

WO9401408

Title:
ANILIDE DERIVATIVES

Abstract:

Compounds are described of general formula (I) and salts and solvates thereof, including physiologically acceptable salts and solvates thereof, in which: Z represents either Het, (a), or (b); Het represents an optionally substituted bicyclic or tricyclic ring selected from quinolin-4-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinolin-3-yl, quinolin-2-yl, quinoxalin-2-yl, naphthalen-1-yl, naphthalen-2-yl, indol-2-yl, 4-oxo-4H-1-benzopyran-2-yl, phenazin-1-yl and phenothiazin-1-yl or an aryl substituted monocyclic ring selected from 2-aryl-4-thiazolyl, 2-aryl-5-thiazolyl, 5-aryl-2-thienyl, 2-aryl-4-triazolyl and 1-aryl-4-pyrazolyl where aryl represents a phenyl or pyridyl ring optionally substituted by a halogen atom or a trifluoromethyl, C1-4 alkyl or C1-4 alkoxy group. The above-mentioned bicyclic or tricyclic rings may be unsubstituted or substituted by one, two or three groups selected from C1-4 alkyl and C1-4 alkoxy. Quinolin-4-yl rings may also be substituted in the ring 2 position by phenyl or phenyl substituted by C1-4 alkoxy. Indol-2-yl rings may also be substituted in the ring 3 position by benzoyl; R8 represents a hydrogen or halogen atom or a C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, amino or nitro group; p represent 1; or when R8 represents C1-4 alkoxy p may also represent 2 or 3; R9 represents a hydrogen or halogen atom or a C1-4 alkyl, C1-4 alkoxy or C1-4 alkylthio group; R10 and R11 may each represent a hydrogen atom or together form a bond or a linking atom selected from -O- or -S-; and X represents an oxygen atom or NR12 (where R12 represents a hydrogen atom or a C1-4 alkyl group). The novel compounds of formula (I) can sensitize multi-drug resistant cancer cells to chemotherapeutic agents and may be formulated for use in therapy, particularly to improve or increase the efficacy of an anti-tumour drug.


BEST AVAILABLE COPY

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|---|-----------|--|
| (51) International Patent Classification ⁵ : C07D 217/04, A61K 31/47 C07D 401/12, 335/16 C07C 235/84, 233/80, C07D 215/48 C07D 215/52, 311/86, 217/26 C07D 241/46 | A1 | (11) International Publication Number: WO 94/01408 (43) International Publication Date: 20 January 1994 (20.01.94) |
| (21) International Application Number: PCT/EP93/01802 (22) International Filing Date: 8 July 1993 (08.07.93) (30) Priority data: 9214667.9 10 July 1992 (10.07.92) GB 9214668.7 10 July 1992 (10.07.92) GB 9214675.2 10 July 1992 (10.07.92) GB (71) Applicant (for all designated States except US): LABORATOIRES GLAXO S.A. [FR/FR]; 43, rue Vineuse, F-75016 Paris (FR). (72) Inventors; and (75) Inventors/Applicants (for US only): DUMAITRE, Bernard, André [FR/FR]; DODIC, Nerina [FR/FR]; DAUGAN, Alain, Claude-Marie [FR/FR]; PIANETTI, Pascal, Maurice, Charles [FR/FR]; Laboratoires Glaxo S.A., Centre de Recherches, Z.A. de Courtaboeuf, 25, avenue de Québec, F-91940 Les Ulis (FR). | | (74) Agents: CAFFIN, Lee et al.; Glaxo Holdings plc, Glaxo House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB). (81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> |

(54) Title: ANILIDE DERIVATIVES**(57) Abstract**

Compounds are described of general formula (I) and salts and solvates thereof, including physiologically acceptable salts and solvates thereof, in which: Z represents either Het, (a), or (b); Het represents an optionally substituted bicyclic or tricyclic ring selected from quinolin-4-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinolin-3-yl, quinolin-2-yl, quinoxalin-2-yl, naphthalen-1-yl, naphthalen-2-yl, indol-2-yl, 4-oxo-4H-1-benzopyran-2-yl, phenazin-1-yl and phenothiazin-1-yl or an aryl substituted monocyclic ring selected from 2-aryl-4-thiazolyl, 2-aryl-5-thiazolyl, 5-aryl-2-thienyl, 2-aryl-4-triazolyl and 1-aryl-4-pyrazolyl where aryl represents a phenyl or pyridyl ring optionally substituted by a halogen atom or a trifluoromethyl, C₁₋₄ alkyl or C₁₋₄ alkoxy group. The above-mentioned bicyclic or tricyclic rings may be unsubstituted or substituted by one, two or three groups selected from C₁₋₄ alkyl and C₁₋₄ alkoxy. Quinolin-4-yl rings may also be substituted in the ring 2 position by phenyl or phenyl substituted by C₁₋₄ alkoxy. Indol-2-yl rings may also be substituted in the ring 3 position by benzoyl; R⁸ represents a hydrogen or halogen atom or a C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, amino or nitro group; p represent 1; or when R⁸ represents C₁₋₄ alkoxy p may also represent 2 or 3; R⁹ represents a hydrogen or halogen atom or a C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkylthio group; R¹⁰ and R¹¹ may each represent a hydrogen atom or together form a bond or a linking atom selected from -O- or -S-; and X represents an oxygen atom or NR¹² (where R¹² represents a hydrogen atom or a C₁₋₄ alkyl group). The novel compounds of formula (I) can sensitize multi-drug resistant cancer cells to chemotherapeutic agents and may be formulated for

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|--|----|--------------------------|
| AT | Austria | FR | France | MR | Mauritania |
| AU | Australia | GA | Gabon | MW | Malawi |
| BB | Barbados | GB | United Kingdom | NE | Niger |
| BE | Belgium | GN | Guinea | NL | Netherlands |
| BF | Burkina Faso | GR | Greece | NO | Norway |
| BG | Bulgaria | HU | Hungary | NZ | New Zealand |
| BJ | Benin | IE | Ireland | PL | Poland |
| BR | Brazil | IT | Italy | PT | Portugal |
| BY | Belarus | JP | Japan | RO | Romania |
| CA | Canada | KP | Democratic People's Republic of Korea | RU | Russian Federation |
| CF | Central African Republic | KR | Republic of Korea | SD | Sudan |
| CG | Congo | KZ | Kazakhstan | SE | Sweden |
| CH | Switzerland | LI | Liechtenstein | SI | Slovenia |
| CI | Côte d'Ivoire | LK | Sri Lanka | SK | Slovak Republic |
| CM | Cameroon | LU | Luxembourg | SN | Senegal |
| CN | China | LV | Latvia | TD | Chad |
| CS | Czechoslovakia | MC | Monaco | TG | Togo |
| CZ | Czech Republic | MG | Madagascar | UA | Ukraine |
| DE | Germany | ML | Mali | US | United States of America |
| DK | Denmark | MN | Mongolia | UZ | Uzbekistan |
| ES | Spain | | | VN | Viet Nam |
| FI | Finland | | | | |

ANILIDE DERIVATIVES


This invention relates to anilide derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their medical use. In particular it relates to compounds and compositions which are capable of sensitizing multidrug-resistant cancer cells to chemotherapeutic agents.

In many patients, the efficacy of cancer chemotherapy is initially poor or decreases after initial treatment due to the development of resistance to anticancer drugs, known as multidrug-resistance. Multidrug-resistance is a process whereby malignant cells become resistant to structurally diverse chemotherapeutic agents following treatment with a single anti-tumour drug. This acquired drug resistance can be a major clinical obstacle in the treatment of cancer. Some tumours are intrinsically multidrug-resistant, and hence do not respond to chemotherapy.

It has been shown that this type of resistance can be reversed by some calcium channel blockers such as nifedipine and verapamil, by antiarrhythmic agents such as amiodarone and quinidine, as well as by natural products such as cepharanthine. However, these compounds exert their multidrug resistant cell sensitizing activity only at very high doses, well above their intrinsic toxic level, and this severely limits their clinical use in the field of cancer chemotherapy.

A novel group of compounds has now been found which can sensitize multidrug-resistant cancer cells to chemotherapeutic agents at dose levels at which these novel compounds show no toxicity.

Thus, the present invention provides a compound of formula (I):



and salts and solvates thereof, including physiologically acceptable salts and solvates thereof, in which:

A represents an oxygen or a sulphur atom, a bond or a group $(\text{CH}_2)_l\text{NR}^7$ (where l represents zero or 1 and R^7 represents a hydrogen atom or a methyl group);

5 B represents a C_{1-4} alkylene chain optionally substituted by a hydroxyl group, except that the hydroxyl group and moiety A cannot be attached to the same carbon atom when A represents an oxygen or sulphur atom or a group $(\text{CH}_2)_l\text{NR}^7$, or when A represents a bond B may also represent a C_{2-4} alkenylene chain;

10 R^1 represents a hydrogen atom or a C_{1-4} alkyl group;

m represents 1 or 2;

R^2 represents a hydrogen or a halogen atom, or a C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-4} alkylthio group;


R^3 represents a hydrogen atom or a C_{1-4} alkoxy group;

15 R^4 represents a hydrogen atom or a C_{1-4} alkyl or C_{1-4} alkoxy group;

R^5 represents a hydrogen atom or R^1 and R^5 together form a group $-(\text{CH}_2)_n-$ where n represents 1 or 2;

R^6 represents a hydrogen atom or a C_{1-4} alkoxy group;


the group




20

is attached at the benzene ring 3 or 4 position relative to the carboxamide substituent, provided that when the group is attached at the benzene ring 3 position then R^4 must be attached at the benzene ring 6 position; and

Z represents either Het,



or



5

Het represents an optionally substituted bicyclic or tricyclic ring selected from quinolin-4-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinolin-3-yl, quinolin-2-yl, quinoxalin-2-yl, naphthalen-1-yl, naphthalen-2-yl, indol-2-yl, 4-oxo-4H-1-benzopyran-2-yl, phenazin-1-yl and phenothiazin-1-yl or an aryl substituted monocyclic ring selected from 2-aryl-4-thiazolyl, 2-aryl-5-thiazolyl, 5-aryl-2-thienyl, 2-aryl-4-triazolyl and 1-aryl-4-pyrazolyl where aryl represents a phenyl or pyridyl ring optionally substituted by a halogen atom or a trifluoromethyl, C₁₋₄ alkyl or C₁₋₄ alkoxy group. The above mentioned bicyclic or tricyclic rings may be unsubstituted or substituted by one, two or three groups selected from C₁₋₄ alkyl and C₁₋₄ alkoxy. Quinolin-4-yl rings may also be substituted in the ring 2 position by phenyl or phenyl substituted by C₁₋₄ alkoxy. Indol-2-yl rings may also be substituted in the ring 3 position by benzoyl;

R⁸ represents a hydrogen or halogen atom or a C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, amino or nitro group;

p represents 1; or when R⁸ represents C₁₋₄ alkoxy p may also represent 2 or 3;

R⁹ represents a hydrogen or halogen atom or a C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkylthio group;

R^{10} and R^{11} may each represent a hydrogen atom or together form a bond or a linking atom selected from -O- or -S-; and

X represents an oxygen atom or NR^{12} (where R^{12} represents a hydrogen atom or a C_{1-4} alkyl group).

- 5 As used herein, an alkyl group, either as such or as part of an alkoxy or alkylthio group may be a straight chain or branched chain alkyl group, for example a methyl, ethyl or prop-2-yl group.

A halogen substituent may be a fluorine, chlorine, bromine or iodine atom.

- 10 The groups represented by R^8 and R^9 may be situated at any available positions in the relevant benzene rings.

Examples of the chain -A-B-CH₂- include -(CH₂)₂-, -(CH₂)₃-, -(CH₂)₄-, -(CH₂)₅-, -CH₂NMe(CH₂)₂-, -CH=CHCH₂-, -CH₂CH=CHCH₂-, -CH(OH)CH₂-, -O(CH₂)₂-, -O(CH₂)₃-, -OCH₂CH(OH)CH₂-, -NH(CH₂)₂-, -S(CH₂)₂- and -S(CH₂)₃-.

- 15 When R^1 represents a hydrogen atom or a C_{1-4} alkyl group, preferably R^1 represents a C_{1-4} alkyl (e.g. methyl) group.

R^8 preferably represents a hydrogen or fluorine atom or a C_{1-4} alkoxy (e.g. methoxy), C_{1-4} alkyl (e.g. methyl) or C_{1-4} alkythio (e.g. methylthio) group.


- 20 R^9 preferably represents a hydrogen atom or a C_{1-4} alkoxy (e.g. methoxy) group.

- 25 A preferred class of compounds of formula (I) is that in which R^2 represents a hydrogen atom or a C_{1-4} alkoxy (e.g. methoxy) group, R^3 represents a hydrogen atom or a C_{1-4} alkoxy (e.g. methoxy) group and R^6 represents a hydrogen atom or a C_{1-4} alkoxy (e.g. methoxy) group, provided that at least one of R^2 , R^3 and R^6 represents a C_{1-4} alkoxy (e.g. methoxy) group. A particularly preferred class of compounds of formula (I) is that in which R^2 and R^3 each represent a C_{1-4} alkoxy (e.g. methoxy) group and R^6 represents a hydrogen atom.

R⁴ preferably represents a hydrogen atom or a methyl, ethyl, methoxy or ethoxy group. Compounds of formula (I) in which R⁴ represents a hydrogen atom are particularly preferred.

5 A preferred group of compounds of formula (I) is that in which m represents 1 and R¹ and R⁵ together form a group -(CH₂)₂-, and physiologically acceptable salts and solvates thereof.

A particular group of compounds of formula (I) is that of formula (Ia)



10

wherein Z is as defined in formula (I) above;


A represents an oxygen or a sulphur atom or a bond;

B represents an unsubstituted C₁₋₄ alkylene chain;

15 R² and R³ each independently represents a C₁₋₄ alkoxy group; (eg methoxy); and physiologically acceptable salts and solvates thereof.

A particular group of compounds of Formula (Ia) are compounds in which Z represents Het as previously defined.


Another particular group of compounds of Formula (Ia) are compounds in which Z represents



20

wherein R^8 represents a hydrogen or halogen atom or a C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio or nitro group, R^9 represents a hydrogen or halogen atom or a C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-4} alkylthio group and R^{10} and R^{11} are as previously defined.

- 5 A further particular group of compounds of formula (Ia) are compounds in which Z represents



- 10 wherein R^8 represents a hydrogen or halogen atom or a C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio or nitro group, R^9 represents a hydrogen or halogen atom or a C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-4} alkylthio group and X represents an oxygen atom or NH.

Particularly preferred compounds of formula (Ia) are those in which R^8 represents a hydrogen or fluorine atom or a C_{1-4} alkoxy (e.g. methoxy) or C_{1-4} alkyl (e.g. methyl) group and R^9 represents a hydrogen atom.

- 15 It is to be understood that the present invention includes all combinations of the aforementioned particular and preferred groups.

- 20 Suitable physiologically acceptable salts of the compounds of formula (I) include acid addition salts formed with organic or inorganic acids, for example, hydrochlorides, hydrobromides, sulphates, alkyl- or arylsulphonates (e.g. methanesulphonates or *p*-toluenesulphonates), phosphates, acetates, citrates, succinates, lactates, tartrates, fumarates and maleates. The solvates may, for example, be hydrates.

- 25 Other salts which are not physiologically acceptable may be useful in the preparation of compounds of formula (I) and these form a further part of the invention.

The ability of the compounds of formula (I) to sensitize multidrug-resistant cells has been demonstrated in vitro in the multidrug-resistant Chinese hamster ovary cell line (described by Bech-Hansen et al., J. Cell. Physiol., 1976, 88, 23-32) and the multidrug-resistant human mammary carcinoma line (described by Batist et al., (J. Biol. Chem., 1986, 261, 1544-1549) using an assay similar to that described by Carmichael et al., Cancer Research, 1987, 47, 936.

The ability of the compounds of formula (I) to sensitize multidrug-resistant cells has also been demonstrated in vivo in the tumour line P388R (described by Johnson et al., Cancer Treat. Rep., 1978, 62, 1535-1547). The methodology used is similar to that described by Boesch et al., Cancer Research, 1991, 51, 4226-4233. However, in our study the compounds were administered orally, intravenously or intraperitoneally in a single dose.

The present invention accordingly provides a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in therapy, more particularly for use in the treatment of a mammal, including a human, which is suffering from cancer to :

- (a) improve or increase the efficacy of an antitumour drug; or
- (b) increase or restore sensitivity of a tumour to an antitumour drug; or
- (c) reverse or reduce resistance, whether acquired, induced or innate, of a tumour to an antitumour drug.

The present invention also provides a method of treatment of a mammal, including a human, which is suffering from cancer, which method comprises administering to said mammal an effective amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof to :

- (a) improve or increase the efficacy of an antitumour drug; or
- (b) increase or restore sensitivity of a tumour to an antitumour drug; or
- (c) reverse or reduce resistance, whether acquired, induced or innate, of a tumour to an antitumour drug.

In another aspect, the present invention provides the use of a compound of formula (I) or a physiologically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of a mammal, including a human, which is suffering from cancer to :

- 5 (a) improve or increase the efficacy of an antitumour drug; or
- (b) increase or restore sensitivity of a tumour to an antitumour drug; or
- (c) reverse or reduce resistance, whether acquired, induced or innate, of a tumour to an antitumour drug.

10 It will be appreciated that the compounds according to the present invention are administered in conjunction with an antitumour drug. Thus, in a further aspect, the present invention provides a product containing a compound of formula (I) or a physiologically acceptable salt or solvate thereof and an antitumour drug as a combined preparation for simultaneous, separate or sequential use in treating cancer, more particularly to :

- 15 (a) improve or increase the efficacy of said antitumour drug; or
- (b) increase or restore sensitivity of a tumour to an antitumour drug; or
- (c) reverse or reduce resistance, whether acquired, induced or innate, of a tumour to an antitumour drug.

20 Examples of suitable antitumour drugs for use in conjunction with compounds of the present invention include Vinca alkaloids (e.g. vincristine, vinblastine and vinorelbine), anthracyclines (e.g. daunorubicin, doxorubicin and aclarubicin), taxol and derivatives thereof (e.g. taxotere), podophyllotoxins (e.g. etoposide and VP16), mitoxantrone, actinomycin, colchicine, gramicidine D, amsacrine or

25 any drug having cross-resistance with the above drugs characterised by the so-called MDR phenotype.

It will be appreciated that if administration of the two drugs is not simultaneous, the delay in administering the second of the active ingredients should not be such as to lose the beneficial effect of the combination.

Thus, in a further aspect, the present invention provides a compound of formula (I) or a physiologically acceptable salt or solvate thereof and an anticancer drug in the presence of each other in the human or non-human animal body for use in treating cancer, more particularly to :

- 5 (a) improve or increase the efficacy of said antitumour drug; or
- (b) increase or restore sensitivity of a tumour to an antitumour drug; or
- (c) reverse or reduce resistance, whether acquired, induced or innate, of a tumour to an antitumour drug.

10 Some tumours are often intrinsically multidrug-resistant, notably colon carcinomas, renal cell carcinomas, hepatomas and adrenocortical carcinomas.

Other types of tumour are often initially sensitive but can become multidrug-resistant, notably leukaemias, lymphomas, myelomas, paediatric tumours (e.g. neuroblastomas), sarcomas, and breast, ovarian and lung cancers.

15 Hence the compounds of the invention are particularly useful in the treatment of mammals, including humans, receiving chemotherapy for one of the above types of cancer.

20 In using a compound of formula (I) or a physiologically acceptable salt or solvate thereof and an antitumour drug it may be preferable to employ the active ingredients in the form of separate pharmaceutical formulations, although a single combined formulation can be used as demonstrated hereinafter. However, in the latter formulation both active ingredients must of course be stable and mutually compatible in the particular formulation employed.

25 Pharmaceutical formulations of suitable antitumour drugs and appropriate dosages and dosage rates will generally correspond with those one would use if administering the antitumour drug alone to treat a tumour.

Suitable pharmaceutical formulations and appropriate dosages and dosage rates of compounds of formula (I) and physiologically acceptable salts and solvates thereof are described hereinafter.

Thus, in a further aspect, the invention provides a pharmaceutical composition which comprises a compound of formula (I) or a physiologically acceptable salt or solvate thereof together with one or more physiologically acceptable carriers or excipients.

5 In another aspect, the present invention provides a pharmaceutical composition which comprises an active amount of a compound of formula (I) or a physiologically acceptable salt or solvate thereof for use in the treatment of a mammal which is suffering from cancer, to :

- (a) improve or increase the efficacy of an antitumour drug; or
- 10 (b) increase or restore sensitivity of a tumour to an antitumour drug; or
- (c) reverse or reduce resistance, whether acquired, induced or innate, of a tumour to an antitumour drug.

The compounds according to the invention may be formulated for oral, buccal, parenteral or rectal administration, of which oral and parenteral are preferred.

15 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium
20 hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. sodium lauryl sulphate or sodium starch glycolate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with
25 water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g. sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g. lecithin or acacia); non-aqueous vehicles (e.g. almond oil, oily esters, ethyl alcohol or fractionated
30 vegetable oils); and preservatives (e.g. methyl or propyl-p-hydroxybenzoates or

sorbic acid). The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

- 5 For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.


- 10 The compounds of the invention may be formulated for parenteral administration by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily, aqueous or alcoholic vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

- 15 The compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.


- 20 A proposed daily dose of the compounds of the invention for administration to a human (of approximately 70kg body weight) is about 10mg to 1000mg, more preferably about 25mg to 500mg. It will be appreciated that it may be necessary to make routine variations to the dosage, depending on the age and condition of the patient, and the route of administration. For example, a daily dose of about 1mg/kg may be appropriate for administration to a human by infusion. The daily dose may be given as a single unit or as two or more subunits administered after appropriate time intervals.
- 25

Compounds of general formula (I) and physiologically acceptable salts and solvates thereof may be prepared by the general methods outlined hereinafter. In the following description, the groups Z, R¹ to R⁶, m, A and B are as defined for compounds of formula (I) unless otherwise specified.

Thus according to a first general process (A), a compound of formula (I) may be prepared by reacting a compound of formula (II):



with a compound of formula (III)




5

10


The reaction may be effected using a coupling reagent standardly used in peptide synthesis, such as dicyclohexylcarbodiimide (optionally in the presence of 1-hydroxybenzotriazole), diphenylphosphoryl azide or N,N'-carbonyldiimidazole. The reaction may be conveniently effected in an inert solvent such as an ether (e.g. tetrahydrofuran), a halogenated hydrocarbon (e.g. dichloromethane), an amide (e.g. dimethylformamide) or a ketone (e.g. acetone), and at a temperature of, for example, -10 to +100°C, more preferably at about room temperature.

15

According to another general process (B), a compound of formula (I) may be prepared by reacting a compound of formula (IV):




wherein Q represents a halogen (e.g. bromine) atom, with a compound of formula (V):



or a salt thereof. The reaction may be effected in the presence of an acid acceptor such as an alkali metal carbonate (e.g. potassium carbonate), in the presence or absence of a solvent, at an elevated temperature (e.g. 50 to 120°C). Suitable solvents include ketones (e.g. acetone, methylethylketone or methylisopropylketone) and alcohols (e.g. ethanol or isopropanol).

Compounds of formula (III) may be prepared according to the methodology described in published European Application 0494623.

Compounds of formula (IV) may be prepared by the reaction of a compound of formula (II) as defined previously, with a compound of formula (VI):



wherein Q represents a halogen (e.g. bromine) atom, under the conditions described in process (A) above for the reaction of a compound of formula (II) with a compound of formula (III).

Intermediates of formula (IV) are novel compounds and represent a further aspect of the present invention.

Compounds of formula (II) are either known in the art or may be prepared by conventional methods, for example as described in the Examples section hereinafter.

Compounds of formulae (V) and (VI) are either known in the art or may be prepared according to the methodology described in published European Application 0494623.

Where it is desired to isolate a compound of the invention as a salt, for example a physiologically acceptable salt, this may be achieved by reacting the compound of formula (I) in the form of the free base with an appropriate acid, preferably with an equivalent amount, in a suitable solvent such as an alcohol (e.g. ethanol or methanol), an aqueous alcohol (e.g. aqueous ethanol), a

halogenated hydrocarbon (e.g. dichloromethane), an ester (e.g. ethyl acetate) or an ether (e.g. tetrahydrofuran), or a mixture of two or more of such solvents.

Physiologically acceptable salts may also be prepared from other salts, including other physiologically acceptable salts, of the compound of formula (I) using conventional methods.

The invention is further illustrated by the following Intermediates and Examples which are not intended to limit the invention in any way. All temperatures are in °C. ¹H NMR spectra were obtained for dilute solutions in CDCl₃ unless otherwise stated. Solvents were dried, where indicated, over sodium sulphate. Silica gel used for column chromatography was Merck 60, 230-400 mesh. The following abbreviations are used: THF - tetrahydrofuran; DMF - dimethylformamide.

Intermediate 1

Ethyl 3,4-dihydro-6-methoxy-3-oxo-2-quinoxalinecarboxylate

2-amino-4-methoxyaniline (25g) triethylamine (25.4 ml) and ethanol (250 ml) were stirred under nitrogen at 5°. Diethyl bromomalonate (40.1 ml) in ethanol (50 ml) was added dropwise over 30 min. The mixture was stirred at 5° for 30 minutes. After 16 hours at room temperature, the precipitate was filtered off and stirred in water (800 ml) containing 1N hydrochloric acid (100 ml) for 1 hour. The mixture was filtered. The residue was washed with water and dried in vacuo to give the title compound (15.3 g) as a solid, mp : 227°.

Intermediate 2

(a) Ethyl 3-chloro-6-methoxy-2-quinoxalinecarboxylate

Phosphorous oxychloride (46 ml) was added to Intermediate 1 (10g). The mixture was heated at 100° for one hour, allowed to cool, and then carefully poured into ice (800 g). The pH of this mixture was adjusted to 3 by addition of aqueous ammonia. The resulting yellow solid was filtered off, washed with water, and recrystallised from aqueous acetone to give the title compound (10.08 g) as a solid, mp = 75°.

The following compound was prepared in a similar manner :

(b) Ethyl 3-chloro-6,7-dimethyl-2-quinolaxinecarboxylate

The title compound (10.7 g) was obtained as a solid, mp = 115° from ethyl 3,4-dihydro-3-oxo-6,7-dimethyl-2-quinoxalinecarboxylate * (10 g).

5 * Chem. Abstracts 41, 3469c.

Intermediate 3

(a) 3-Methoxy-6,7-dimethyl-2-quinoxalinecarboxylic acid

10 Intermediate 2(b) (2g) was added to a solution of sodium (0.43g) in dry methanol (100 ml). The solution was refluxed for 1 hour, cooled to room temperature and water (20 ml) was added. The solution was refluxed for 1 hour. The cool solution was filtered off. The filtrate was acidified to pH 3 with 2N hydrochloric acid. The product crystallised and was then filtered, washed with water and dried in vacuo to give the title compound (1.59g) as a solid, mp = 180 - 182°.

15 The following compound was prepared in a similar manner :

(b) 3-Ethoxy-6,7-dimethyl-2-quinoxalinecarboxylic acid

The title compound (0.88g) was obtained as a solid, mp = 116°, from Intermediate 2(b) (1.3g) in ethanol.

Intermediate 4

20 Ethyl 6-methoxy-3-ethylthio-2-quinoxalinecarboxylate

25 To a suspension of sodium hydride (1.8g) in THF was added a solution of ethanethiol in dry THF (30 ml). After 15 min, a solution of Intermediate 2(a) (10g) in dry THF (50 ml) was added. The mixture was stirred at room temperature for 16 hours. The precipitate was filtered off and the filtrate was evaporated. The residue was extracted with dichloromethane, washed with water, dried, concentrated in vacuo and recrystallised from isopropanol (50 ml), to give the title compound (5g) as a solid, mp = 70°.

Intermediate 5Ethyl 6-methoxy-2-quinoxalinecarboxylate

To a solution of Intermediate 4 (5g) was carefully added Raney nickel (80g). The mixture was stirred at room temperature for 1 hour. The Raney nickel was filtered off and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel eluting with cyclohexane:ethylacetate (70 : 30) to give the title compound (2.5 g) as a solid.

NMR includes δ 1.48 (3H,t,CH₃); 3.84(3H,s,OCH₃); 4.57(2H,q,CH₂).

Intermediate 610 6-Methoxy-2-quinoxalinecarboxylic acid

To a solution of Intermediate 5 (2.5g) in ethanol (60ml) was added an aqueous solution of 30% sodium hydroxide. The mixture was refluxed for 30 minutes. After evaporation, the mixture was acidified by addition of 1N hydrochloric acid. The white crystals were filtered off and dried to give the title compound (2 g) as a solid, mp = 248°.

Intermediate 72-Methoxy-3'-methylbenzophenone

A mixture of 2-methoxybenzonitrile (4.3 ml) and the Grignard reagent of m-bromotoluene (6.6 g) in ether was refluxed for 1h and hydrolysed with dilute hydrochloric acid with heating. The aqueous layer was then extracted with ether, and the resultant organic layer was dried and evaporated to give the title compound (5.5 g) as an oil.

Intermediate 83-(2-Methoxybenzoyl)benzoic acid

25 A solution of Intermediate 7 (5.4 g) in a mixture of pyridine (50 ml) and water (70 ml) was heated to 50° and treated dropwise with potassium permanganate (19g). The mixture was then refluxed for 2 h, cooled to room temperature,

filtered and the salts were washed with hot water. The aqueous solution was then acidified with sulphuric acid and extracted with dichloromethane. The organic layer was then dried and evaporated to give the title compound (4.4g) as a solid, mp = 170-172°.

5 Intermediate 9

(a) 1-(3-Bromopropoxy)-3-methoxy-4-nitrobenzene

10 A mixture of 3-methoxy-4-nitrophenol (Intermediate 18 in EP-A-494623) (2.4g), 1,3-dibromopropane (7.5ml) and potassium carbonate (2.2g) in DMF (30ml) was stirred at room temperature for 24h. The mixture was filtered and the filtrate was evaporated to dryness. The residue was treated with water and extracted with dichloromethane. The organic extract was then washed with 5% sodium hydroxide solution and brine, dried and concentrated in vacuo to give the title compound (3.5g) as an oil.

15 NMR includes δ 2.3 (2H,m,CH₂), 3.6 (2H,t,CH₂Br), 3.8 (3H,s,OCH₃), 4.1 (2H,t,CH₂O).

The following compounds were prepared in a similar manner to Intermediate 9 (a):

(b) 1-(4-Bromobutoxy)-4-nitrobenzene

The title compound was obtained from 4-nitrophenol and 1,4-dibromobutane.

20 NMR includes δ 4.01 (2H,m,CH₂Br), 3.4 (2H,m,CH₂Ar).

(c) 1-(3-Bromopropoxy)-3-methyl-4-nitrobenzene

The title compound (33g) was obtained as an oil from 3-methyl-4-nitrophenol (25g) and 1,3-dibromopropane (83ml).

25 NMR includes δ 2.3 (2H,m,CH₂), 2.5 (3H,s,CH₃), 3.6 (2H,t,CH₂Br), 4.1 (2H,t,OCH₂).

Intermediate 10

(a) 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-[3-(3-methoxy-4-nitrophenoxy)propyl]isoquinoline

5 A mixture of Intermediate 9(a) (0.7g), 1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline (0.4g) and potassium carbonate (0.36g) in DMF (25ml) was heated at 60° for 16h. The mixture was filtered and the filtrate was evaporated. The residue was treated with water and extracted with dichloromethane. The organic layer was dried, concentrated, and the resultant residue was purified by column chromatography eluting with dichloromethane:methanol (99:1) to give the title compound (0.64g) as an oil.

10 NMR includes δ 3.8 (9H, 2s, 3 X OCH₃).

The following compounds were prepared in a similar manner to Intermediate 10(a):

(b) 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-[4-(4-nitrophenoxy)butyl]isoquinoline

15 The title compound was obtained from Intermediate 9(b) and 1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline.

NMR includes δ 3.7(2H, s, NCH₂Ar), 3.9(2H, t, OCH₂).

(c) 1,2,3,4-Tetrahydro-6,7-dimethoxy-2-[3-(3-methyl-4-nitrophenoxy)propyl]isoquinoline

20 The title compound (5.3g) was obtained as an oil from Intermediate 9(c) (5.7g) and 1,2,3,4- tetrahydro-6,7-dimethoxyisoquinoline (4.0g).

NMR includes δ 2.5 (3H, s, CH₃), 3.8 (6H, s, 2 X OCH₃)

(d) N-Methyl-N-(4-nitrobenzyl)veratrylamine

The title compound was obtained as an orange oil from 4-nitrobenzylbromide and N-methylveratrylamine.

25 NMR includes δ 3.8 (6H, s, 2 x OCH₃), 2.2 (3H, s, NCH₃), 3.65 (2H, s, NCH₂C₆H₄NO₂-p), 3.5(2H, s, NCH₂C₆H₃(OCH₃)₂).

(e) N-Methyl-N-[3-(4-nitrophenoxy)propyl]benzylamine

The title compound was obtained as the hydrochloride salt (from diethyl ether) from 1-(3-bromopropoxy)-4-nitrobenzene and N-methylbenzylamine. mp = 170-172°.

Intermediate 11(a) 2-Methoxy-4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]propoxy]benzenamine

5 A solution of Intermediate 10(a) (0.64g) in ethanol (25ml) was hydrogenated at room temperature and atmospheric pressure in the presence of 10% palladium on carbon (60mg). After hydrogen absorption was completed, the catalyst was filtered off and the solution was concentrated in vacuo to give the title compound (0.4g) as a solid.

NMR includes δ 3.8 (9H,s, 3 X OCH₃), 3.0 (2H,bs,NH₂).

10 The following compounds were prepared in a similar manner to Intermediate 11(a):

(b) 4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-isoquinoliny)]butoxy]benzenamine

The title compound was obtained from Intermediate 10(b), mp = 114°.

15 (c) 2-Methyl-4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]propoxy]benzenamine

The title compound (4.8g) was obtained as an oil (which subsequently crystallised) from Intermediate 10 (c) (5.3g).

NMR includes δ 2.1 (3H,s,CH₃), 3.8 (6H,s, 2 X OCH₃).

(d) N-(4-Aminobenzyl)-N-methylveratrylamine

20 The title compound was obtained as a yellow oil from Intermediate 10(d).

NMR includes δ 3.75 (s, 6H 2 X OCH₃), 3.5(4H, 2 X NCH₂Ph), 2.1(3H, s, NCH₃).

(e) 4-[3-(N-methylbenzylamino)propoxy]aniline

25 The title compound was obtained as an oil from Intermediate 10(e). NMR includes δ 3.9 (t, 2H, O-CH₂), 3.4(s, 2H, CH₂Ph), 2.1(t, 2H, N-CH₂), 2.0(s, 3H, N-CH₃), 1.85(m, 2H, CH₂).

Intermediate 121-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)-3-(4-nitrophenoxy)-2-propanol

5 A mixture of 1,2-epoxy-3-(4-nitrophenoxy)propane (4g) and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (5.4g) in isopropanol (100ml) was heated under reflux for 3h and evaporated. The residue was purified by column chromatography to give the title compound (7.6g) as a yellow oil which solidified on standing.

Intermediate 13

10 1-(4-Aminophenoxy)-3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)-2-propanol

A solution of Intermediate 12 (4g) in ethanol (100ml) was hydrogenated at room temperature in the presence of 10% palladium on carbon (0.4g). After the hydrogen absorption was completed, the catalyst was filtered off and the filtrate concentrated in vacuo to give the title compound (3.5g) as an off white solid, mp = 106°.

15

Intermediate 143-(3-Methoxybenzoyl)benzoic acid

A solution of 3-methoxy-3'-methylbenzophenone* (8 g) in a mixture of pyridine (50 ml) and water (100 ml) was heated to 50° and treated dropwise with potassium permanganate (22 g). The mixture was then refluxed for 12 h, cooled to room temperature, filtered and the salts washed with hot water. The aqueous solution was then acidified with sulphuric acid and the resultant solid was filtered off and recrystallised from a mixture of ethanol/water to give the title compound (5.8 g) as a solid, mp : 160°.

20

25

* W.E. Bachmann and J.W. Ferguson, J.A.C.S., 56, 2081-4 (1934).

Intermediate 153-(4-Fluorobenzoyl)benzoic acid

5 A suspension of 4'-fluoro-3-methylbenzophenone* (1.8 g) in water (70 ml) was treated dropwise with potassium permanganate (5.3 g) and the mixture was refluxed for 12 h. After cooling to room temperature, the salts were filtered and washed with hot water. The aqueous solution was then acidified with concentrated hydrochloric acid and the resultant solid was filtered off and dried to give the title compound (1.2 g) as a solid, mp : 180°.

10 * A. Allais et al., Eur. J. Med. Chem.- Chemica therapeutica, 9, n4, p 381-389 (1974).

Intermediate 16Methyl 5-(3-fluorobenzoyl)-2-methoxybenzoate

15 Aluminium trichloride (16.2 g) and 3-fluorobenzoyl chloride (7.5 ml) were added to 1,2-dichloroethane (120 ml) at room temperature. The mixture was cooled to - 5° and salicylic acid (8.3 g) was added portionwise and the mixture was heated to 40°. After 12 h at 40°, the mixture was cooled, poured into ice and acidified with 2N hydrochloric acid. Extraction with ethyl acetate and evaporation gave a white solid. A portion (10 g) of the solid was dissolved in dimethylsulphoxide (60 ml) and potassium carbonate (16 g) was added. After 1 h at room temperature, iodomethane (9.6 ml) was added and the mixture was heated at 20 40° for 3 h. After cooling, the mixture was poured in to ice and the precipitate was purified by chromatography eluting with toluene/ethyl acetate (90/10) to give the title compound (7 g) as a solid, mp : 140°.

Intermediate 1725 N-Benzyl-N-methyl-2-(4-nitrophenoxy)acetamide

MP 95-96°. Prepared from (4-nitrophenoxy)acetic acid and N-methylbenzylamine according to the method used in Intermediate 34 (a) in EP-A-494623.

Intermediate 18

N-Benzyl-N-methyl-2-(4-aminophenoxy)acetamide as an oil.

5 NMR includes signals at δ 4.8(s, 2H, O-CH₂-CO), 3.7(s, 2H, CH₂Ph), 2.8(s, 3H, N-CH₃). Prepared from Intermediate 17 according to the method used in Intermediate 35(a) in EP-A-494623.

Intermediate 19

10 4-[2-(N-Methylbenzylamino)ethoxy]aniline as a red oil. NMR includes signals at δ 3.9(t, 2H, O-CH₂), 3.5(s, 2H, CH₂-Ph), 2.1(t, 2H, N-CH₂), 2.0(s, 3H, N-CH₃). Prepared from Intermediate 18 according to the method used in Intermediate 36(a) in EP-A-494623.

Intermediate 205-(3-Fluorobenzoyl)-2-methoxybenzoic acid

15 To a suspension of Intermediate 16 (4.3 g) in water (50 ml) was added potassium hydroxide (2.5 g) and the mixture was heated at reflux for 2 h. After cooling, the solution was acidified with 1N hydrochloric acid and the white precipitate was filtered off and dried to give the title compound (4 g) as a solid, mp : 200°.

Intermediate 21Methyl 5-benzoyl-2-methoxybenzoate

20 Aluminium trichloride (16.2 g) and benzoyl chloride (7 ml) were added to 1,2-dichloroethane (100 ml) at room temperature. The mixture was cooled to - 5° and salicylic acid (8.3 g) was added portionwise and the mixture was heated to 60°. After 12 h at 60°, the mixture was cooled, poured into ice and acidified with 2N hydrochloric acid. Extraction with ethyl acetate and evaporation gave a
25 white solid which was dissolved in dimethylsulphoxide (100 ml) and potassium carbonate (24 g) was added. After 1 h at room temperature, iodomethane (15 ml) was added and the mixture was heated at 40° for 3 h. After cooling, the mixture was poured in to ice and the precipitate was purified by chromatography

on silica gel eluting with toluene/ethyl acetate (90/10) to give the title compound (11.5 g) as a solid, mp : 88°.

Intermediate 22

5-Benzoyl-2-methoxybenzoic acid

- 5 To a suspension of Intermediate 21 (7 g) in water (45 ml) was added potassium hydroxide (4.3 g) and the mixture was heated at reflux for 2 h. After cooling, the solution was acidified with 1N hydrochloric acid and the white precipitate was filtered off and dried to give the title compound (6.1 g) as a solid, mp : 150°.

Intermediate 23

10 Methyl 5-(3-methoxybenzoyl)-2-methoxybenzoate

- Aluminium trichloride (9.4 g) and 3-methoxybenzoyl chloride (5 ml) were added to 1,2-dichloroethane (60 ml) at room temperature. The mixture was cooled to -5° and salicylic acid (4.8 g) was added portionwise and the mixture was heated to 40°. After 12 h at 40°, the mixture was cooled, poured into ice and acidified with 2N hydrochloric acid. Extraction with ethyl acetate and evaporation gave an oil which was dissolved in dimethylsulphoxide (50 ml) and potassium carbonate (20 g) was added. After 1 h at room temperature, iodomethane (10 ml) was added and the mixture was heated at 40° for 3 h. After cooling, the mixture was poured into ice and the oil was purified by chromatography eluting with toluene/ethyl acetate (90/10) to give the title compound (4.1 g), as a yellow oil.

Intermediate 24

5-(3-Methoxybenzoyl)-2-methoxybenzoic acid

- 25 To a suspension of Intermediate 23 (3.5 g) in water (40 ml) was added potassium hydroxide (1.9 g) and the mixture was heated at reflux for 2 h. After cooling, the solution was acidified with 1N hydrochloric acid and the white precipitate was filtered off and dried to give the title compound (2.5 g) as a solid, mp : 132°.

Example 1N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]phenyl]-2-quinoxalinecarboxamide

5 A mixture of 2-quinoxalinecarboxylic acid (0.5g) and 1-hydroxybenzotriazole (0.39g) in DMF (20ml) was stirred at room temperature for 10min. 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]benzenamine (Intermediate 5(b) in EP-A-494623) (0.78g) was then added, followed by dicyclohexylcarbodiimide (0.59g) and the mixture was stirred at room temperature for 16h and then filtered. The filtrate was concentrated in vacuo, treated with dilute sodium hydroxide solution and extracted with methylene chloride. The combined, dried, organic extracts were evaporated and the residue was purified by column chromatography on silica gel eluting with methylene chloride/methanol (9:1) to give the title compound (0.62g) as a white solid, after crystallisation from methanol, mp = 155°.

15 Analysis Found : C, 71.41; H, 6.20; N, 11.62;

C₂₉H₃₀N₄O₃ (0.25H₂O) Requires : C, 71.51; H, 6.31; N, 11.50%.

The following compounds were prepared in a similar manner:

Example 2

20 N-[4-(3-(Methylveratrylamino)propyl)phenyl]-2-(4-methoxyphenyl)-4-quinolinecarboxamide

The coupling of 2-(4-methoxyphenyl)-4-quinolinecarboxylic acid (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.9g) gave, after crystallisation from ethanol, the title compound as a solid (0.75g), mp = 105°.

25 Analysis Found : C, 75.24; H, 6.49; N, 7.20;

C₃₆H₃₇N₃O₄ Requires : C, 75.10; H, 6.48; N, 7.30%.

Example 3N-[4-(2-(Methylveratrylamino)ethoxy)phenyl]-2-(3-methoxyphenyl)-4-quinolinecarboxamide

5 The coupling of 2-(3-methoxyphenyl)-4-quinolinecarboxylic acid (0.8g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzenemethanamine (Intermediate 36(b) in EP-A-494623) (0.78g) gave, after crystallisation from diisopropyl ether, the title compound as a solid (0.36g) mp = 97°.

Analysis Found : C, 72.55; H, 6.08; N, 7.23;

C₃₅H₃₅N₃O₅ Requires : C, 72.77; H, 6.11; N, 7.27%.

10 Example 4

N-[4-[2-[(4-Methoxybenzyl)methylamino]ethoxy]phenyl]-6-methyl-2-phenyl-4-quinolinecarboxamide

15 The coupling of 6-methyl-2-phenyl-4-quinolinecarboxylic acid (1.32g) with N-[2-(4-aminophenoxy)ethyl]-4-methoxy-N-methylbenzenemethanamine (Intermediate 36(f) in EP-A-494623) (1.2g) gave the title compound as an oil (0.6g) in the form of an oxalate (from isopropanol), mp = 180-182°.

Analysis Found : C, 67.66; H, 5.78; N, 6.91;

C₃₄H₃₃N₃O₃, C₂H₂O₄, H₂O Requires : C, 67.59; H, 5.83; N, 6.57%.

Example 5

20 N-[4-[2-[(4-Methoxybenzyl)methylamino]ethoxy]phenyl]-6-methoxy-2-phenyl-4-quinolinecarboxamide

25 The coupling of 6-methoxy-2-phenyl-4-quinolinecarboxylic acid (0.84g) with N-[2-(4-aminophenoxy)ethyl]-4-methoxy-N-methylbenzenemethanamine (Intermediate 36(f) in EP-A-494623) (0.87g) gave after crystallisation from methanol, the title compound as a solid (0.25g), mp = 114 -115°.

Analysis Found : C, 73.94; H, 6.06; N, 7.81;
C₃₄H₃₃N₃O₄ Requires : C, 74.56; H, 6.07; N, 7.67%.

Example 6

5 N-[4-(4-(Methylveratrylamino)butyl)phenyl]-6-methoxy-2-phenyl-4-quinolinecarboxamide

The coupling of 6-methoxy-2-phenyl-4-quinolinecarboxylic acid (1.4g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenebutanamine (Intermediate 33(a) in EP-A-494623) (1.65g) gave, after crystallisation from ethanol, the title compound as a solid (0.38g), mp = 148°.

10 Analysis Found : C, 75.26; H, 6.69; N, 6.73;
C₃₇H₃₉N₃O₄ Requires : C, 75.74; H, 6.18; N, 7.16%.

Example 7

N-[4-(2-(Methylveratrylamino)ethyl)phenyl]-1-phenothiazinecarboxamide

15 The coupling of 1-phenothiazinecarboxylic acid* (0.63g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzeneethanamine (Intermediate 33(b) in EP-A-494623) (0.78g) gave the title compound as an oil (0.4g) in the form of a hydrochloride (from diethyl ether), mp = 144°.

20 Analysis Found : C, 64.36; H, 5.98; Cl, 5.24; N, 7.15; S, 5.60;
C₃₁H₃₁N₃O₃S₁, HCl, H₂O Requires : C, 64.18; H, 5.91; Cl, 6.00; N, 7.24; S, 5.53%.

* Brian D Palmer et al., J Med Chem 1988, 31, 707-712.

Example 8

N-[4-(2-(Methylveratrylamino)ethoxy)phenyl]-1-phenazinecarboxamide

25 The coupling of 1-phenazinecarboxylic acid* (0.68g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzenemethanamine

(Intermediate 36(b) in EP-A-494623) (1g) gave, after crystallisation from ethanol, the title compound as a solid (0.55g), mp = 135°.

Analysis Found : C, 71.30; H, 5.78; N, 10.47;

C₃₁H₃₀N₄O₄ Requires : C, 71.24; H, 5.78; N, 10.72%.

5 * Gordon W. Rewcastle et al., J Med Chem. 1987, 30, 843-851.

Example 9

N-[4-[2-[(4-Methoxybenzyl)methylamino]ethoxy]phenyl]-1-phenazinecarboxamide

10 The coupling of 1-phenazinecarboxylic acid (0.68g) with N-[2-(4-aminophenoxy)ethyl]-4-methoxy-N-methylbenzenemethanamine (Intermediate 36 (f) in EP-A-494623) (1g) gave, after crystallisation from ethanol, the title compound as a solid (0.52g), mp = 134°.

Analysis Found : C, 72.89; H, 5.76; N, 11.54;

C₃₀H₂₈N₄O₃ Requires : C, 73.15; H, 5.73; N, 11.37%.

15 Example 10

N-[4-(2-(Methylhomoveratrylamino)ethoxy)phenyl]-1-phenothiazine carboxamide

20 The coupling of 1-phenothiazinecarboxylic acid (0.73g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzeneethanamine (Intermediate 36(a) in EP-A-494623) (1.1g) gave, after crystallisation from ethanol, the title compound as a solid (0.45g), mp = 90°.

Analysis Found : C, 68.98; H, 5.89; N, 7.49; S, 5.59;

C₃₂H₃₃N₃O₄S₁ Requires : C, 69.16; H, 5.98; N, 7.56; S, 5.77%.

Example 11N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)propyl]phenyl]-3-isoquinolinecarboxamide

5 The coupling of 3-isoquinolinecarboxylic acid (0.6g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolyl)propyl]benzenamine (Intermediate 5(b) in EP-A-494623) (1g) gave, after trituration in diethyl ether, the title compound (0.89g) as a solid, mp = 146°.

Analysis

Found : C, 73.87; H, 6.15; N, 8.60;

 $C_{30}H_{31}N_3O_3$

Requires : C, 73.44; H, 6.57; N, 8.56%.

10 Example 12N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)butyl]phenyl]-6,7-dimethyl-2-quinoxalinecarboxamide

15 The coupling of 6,7-dimethyl-2-quinoxalinecarboxylic acid (0.45g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.68g) gave, after crystallisation from isopropanol, the title compound (0.26g) as a solid, mp = 100- 105°.

Analysis

Found : C, 70.82; H, 6.89; N, 10.23;

 $C_{32}H_{36}N_4O_3 (H_2O)$

Requires : C, 70.82; H, 7.05; N, 10.32%.

Example 1320 N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]phenyl]-6(7)-methyl-2-quinoxalinecarboxamide

25 The coupling of 6(7)-methyl-2-quinoxalinecarboxylic acid* (0.5g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623) (0.89g) gave, after crystallisation from acetonitrile, the title compound (1g) as a solid, mp = 147°.

Analysis Found : C, 70.29; H, 6.33; N, 10.38;

$C_{31}H_{34}N_4O_4$ Requires : C, 70.70; H, 6.51; N, 10.64%.

*Chem, Abstracts 53,1358f.

Example 14

5 N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)propyl]phenyl]-6(7)-methyl-2-quinoxalinecarboxamide

10 The coupling of 6(7)-methyl-2-quinoxalinecarboxylic acid (0.5g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propyl]benzenamine (Intermediate 5(b) in EP-A-494623) (0.9g) gave, after crystallisation from isopropanol, the title compound (1.05g) as a solid, mp = 120-126°.

Analysis Found : C, 72.88; H, 6.89; N, 10.69;

$C_{31}H_{34}N_4O_3$ Requires : C, 72.92; H, 6.71; N, 10.97%.

Example 15

15 N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)butyl]phenyl]-6(7)-methoxy-2-quinoxalinecarboxamide

The coupling of Intermediate 6 (0.54g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.9g) gave, after crystallisation from a 1:1 mixture of isopropanol and acetonitrile, the title compound (0.93g) as a solid, mp = 138°.

20 Analysis Found : C, 69.49; H, 6.41; N, 10.30;

$C_{31}H_{34}N_4O_4$ (0.5H₂O) Requires : C, 69.51; H, 6.59; N, 10.44%.

Example 16N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]phenyl]-6(7)-methoxy-2-quinolinecarboxamide

5 The coupling of Intermediate 6 (0.54g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623) (0.89g) gave, after crystallisation from a 1:1 mixture of isopropanol and acetonitrile, the title compound (0.9g) as a solid, mp = 166°.

Analysis

Found : C, 67.24; H, 5.99; N, 10.48;

 $C_{30}H_{32}N_4O_5$ (0.5H₂O) Requires : C, 67.02; H, 6.18; N, 10.42%.10 Example 17N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)propyl]phenyl]-3-quinolinecarboxamide

15 The coupling of 3-quinolinecarboxylic acid (1g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propyl]benzenamine (Intermediate 5(b) in EP-A-494623) (1.2g) gave, after crystallisation from isopropanol, the title compound (1.01g) as a solid, mp = 184-185°.

Analysis

Found : C, 74.40; H, 6.50; N, 8.59;

 $C_{30}H_{31}N_3O_3$

Requires : C, 74.82; H, 6.49; N, 8.73%.

Example 1820 Hydrochloride salt of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)butyl]phenyl]-2-quinolinecarboxamide

25 The coupling of 2-quinolinecarboxylic acid (0.38g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.5g) gave, after crystallisation from isopropanol, the title compound (0.23g) as a solid, mp = 230-235°.

Analysis Found : C, 69.48; H, 6.45; N, 7.46;

$C_{31}H_{34}N_3O_3$ Requires : C, 69.98; H, 6.44; N, 7.90%.

Example 19

5 N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]phenyl]-4-methoxy-2-quinolinecarboxamide

The coupling of 4-methoxy-2-quinolinecarboxylic acid (1g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]benzenamine (Intermediate 5(b) in EP-A-494623) (1g) gave, after crystallisation from isopropanol, the title compound (0.5g) as a solid, mp = 123-125°.

10 Analysis Found : C, 72.70; H, 6.58; N, 8.30;

$C_{31}H_{33}N_3O_4$ Requires : C, 72.78; H, 6.50; N, 8.21%.

Example 20

15 N-[4-[4-(Methylveratrylamino)butyl]phenyl]-2-quinoxalinecarboxamide

The coupling of 2-quinoxalinecarboxylic acid (0.5g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenebutanamine (Intermediate 33(a) in EP-A-494623) (0.94g) gave, after crystallisation from ethanol, the title compound (0.4g) as a solid, mp = 82-85°.

Analysis Found : C, 71.89; H, 6.73; N, 11.75;

$C_{29}H_{32}N_4O_3$ Requires : C, 71.88; H, 6.66; N, 11.56%.

20 Example 21

N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-2-quinoxalinecarboxamide

25 The coupling of 2-quinoxalinecarboxylic acid (0.5g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.62g) gave, after trituration with diethyl ether, the title compound (0.4g) as a solid, mp = 144°.

Analysis Found : C, 72.33; H, 6.55;

C₃₀H₃₂N₄O₃ Requires : C, 72.56; H, 6.49%.

Example 22

5 N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-2-quinoxalinecarboxamide

The coupling of 2-quinoxalinecarboxylic acid (0.5g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623 (1g) gave, after recrystallisation from ethanol, the title compound (0.78g) as a solid, mp = 170-173°.

10 Analysis Found : C, 69.35; H, 6.16; N, 11.27;

C₂₉H₃₀N₄O₄ Requires : C, 69.86; H, 6.06; N, 11.24%.

Example 23

N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-3-methoxy-6,7-dimethyl-2-quinoxalinecarboxamide

15 The coupling of Intermediate 3(a) (0.6g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623 (0.8g) gave, after crystallisation from isopropanol, the title compound (0.47g) as a solid, mp = 158°.

Analysis Found : C, 67.32; H, 6.67; N, 9.80;

20 C₃₂H₃₆N₄O₅ (0.5H₂O) Requires : C, 67.94; H, 6.59; N, 9.90%.

Example 24

N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]phenyl]-3-methoxy-6,7-dimethyl-2-quinoxalinecarboxamide

25 The coupling of Intermediate 3(a) (0.6g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]benzenamine (Intermediate 5(b) in EP-A-

494623) (0.8g) gave, after crystallisation from isopropanol, the title compound (0.75g) as a solid, mp = 164-166°.

Analysis Found : C, 67.32; H, 6.67; N, 9.80;

C₃₂H₃₆N₄O₅ (0.5H₂O) Requires : C, 67.94; H, 6.54; N, 9.90%.

5 Example 25

N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]phenyl]-3-methyl-2-quinoxalinecarboxamide

10 The coupling of 3-methyl-2-quinoxalinecarboxylic acid* (0.5g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.9g) gave, after crystallisation from a 1:1 mixture of isopropanol and acetonitrile, the title compound (0.9g) as a solid, mp = 146°.

Analysis Found : C, 73.13; H, 6.76; N, 10.88;

C₃₁H₃₄N₄O₃ Requires : C, 72.92; H, 6.71; n, 10.97%.

* Chem Abstracts 46,8124c.

15 Example 26

N-[4-[3-(Methylveratrylamino)propyl]phenyl]-5-methoxyindole-2-carboxamide

20 The coupling of 5-methoxyindole-2-carboxylic acid (0.5g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.62g) gave, after crystallisation from isopropanol, the title compound (0.48g) as a solid, mp = 80°.

Anaiysis Found : C, 70.79; H, 6.86; N, 8.02;

C₂₉H₃₃N₃O₄ (0.25H₂O) Requires : C, 70.78; H, 6.86; N, 8.03%.

Example 27N-[4-[3-(Methylveratrylamino)propyl]phenyl]-3-benzoyl-2-indolecarboxamide

5 The coupling of 3-benzoyl-2-indolecarboxylic acid (0.35g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.42g) gave, after crystallisation from ethanol, the title compound (0.30g) as a solid, mp = 156-161°.

Analysis Found : C, 74.25; H, 6.36; N, 7.05;

C₃₅H₃₅N₃O₄ (0.25H₂O) Requires : C, 74.24; H, 6.32; N, 7.42%.

Example 28

10 N-[4-[3-(Methylveratrylamino)propyl]phenyl]-1-naphtalenecarboxamide

The coupling of 1-napththoic acid (0.3 g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.53 g) gave, after crystallisation from diisopropyl ether, the title compound (0.38 g) as a solid, mp : 113-117°.

15 Analysis Found : C, 75.84; H, 6.93; N, 5.92;

C₃₀H₃₂N₂O₃.0.4H₂O Requires : C, 75.73; H, 6.94; N, 5.88%.

Example 29

Oxalate of N-[4-[3-methylveratrylamino]propyl]phenyl]-2-naphtalenecarboxamide

20 The coupling of 2-napththoic acid (0.4 g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.73 g) gave the title compound (0.6 g) as a solid, mp : 203-207°.

Analysis Found : C, 68.76; H, 6.17; N, 5.04;

25 C₃₀H₃₂N₂O₃.C₂H₂O₄ Requires : C, 68.80; H, 6.13; N, 5.01%.

Example 30N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-2-naphtalenecarboxamide

5 The coupling of 2-naphthoic acid (0.6 g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.79 g) gave, after crystallisation from isopropanol, the title compound (0.5 g) as a solid, mp : 165-167°.

Analysis

Found : C,76.84; H,6.92; N,5.59;

 $C_{32}H_{34}N_2O_3 \cdot 0.3H_2O$

Requires : C,76.86; H,6.97; N,5.60%.

10 Example 31N-[4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-2-naphtalenecarboxamide

15 The coupling of 2-naphthoic acid (0.47 g) with 4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]benzenamine (Intermediate 2(c) in EP-A-494623) (0.82 g) gave, after crystallisation from isopropanol, the title compound (0.83 g) as a solid, mp : 162-165°.

Analysis

Found : C,77.28; H,6.50; N,5.91;

 $C_{30}H_{30}N_2O_3$

Requires : C,77.23; H,6.48; N,6.00%.

Example 3220 N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-2-naphtalenecarboxamide

25 The coupling of 2-naphthoic acid (0.3 g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623) (0.58 g) gave, after crystallisation from acetonitrile, the title compound (0.2 g) as a solid, mp : 189-190°.

Analysis

Found : C,74.97; H,6.53; N,5.54;

 $C_{31}H_{32}N_2O_4$

Requires : C,74.98; H,6.50; N,5.64%.

Example 33N-[4-[3-(Methylveratrylamino)propoxy]phenyl]-2-naphtalenecarboxamide

- 5 The coupling of 2-naphthoic acid (0.4 g) with N-[3-(4-aminophenoxy)propyl]-3,4-dimethoxy-N-methylbenzenemethanamine (Intermediate 38(c) in EP-A-494623) (0.76 g) gave, after crystallisation from acetonitrile, the title compound (0.45 g) as a solid, mp : 131-133°.

Analysis

Found : C,74.22; H,6.75; N,5.78;

10 $C_{30}H_{32}N_2O_4$

Requires : C,74.36; H,6.66; N,5.78%.

Example 34Oxalate of N-[4-[3-methylveratrylamino]propyl]phenyl]-1-isoquinolinecarboxamide

- 15 The coupling of 1-isoquinolinecarboxylic acid (0.35 g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(c) in EP-A-494623) (0.53 g) gave the title compound (0.3 g) as a solid, mp : 183-187°.

Analysis

Found : C,66.65; H,6.00; N,7.40;

 $C_{29}H_{31}N_3O_3.C_2H_2O_4$

Requires : C,66.53; H,5.94; N,7.51%.

- 20 Example 35

N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-1-isoquinolinecarboxamide

- 25 The coupling of 1-isoquinolinecarboxylic acid (0.35 g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623) (0.58 g) gave, after crystallisation from isopropanol, the title compound (0.6 g) as a solid, mp : 160°.

Analysis Found : C,72.61; H,6.39; N,8.43;

$C_{30}H_{31}N_3O_4$ Requires : C,72.41; H,6.28; N,8.44%.

Example 36

Oxalate of N-[4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]phenyl]-1-isoquinolinecarboxamide

5

The coupling of 1-isoquinolinecarboxylic acid (0.35 g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propyl]benzenamine (Intermediate 5(b) in EP-A-494623) (0.55 g) gave the title compound (0.5 g) as a solid, mp : 206-209°.

10 Analysis Found : C,66.56; H,5.87; N,7.30;

$C_{30}H_{31}N_3O_3 \cdot C_2H_2O_4 \cdot 0.3H_2O$ Requires : C,66.60; H,5.87; N,7.28%.

Example 37

N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-3-(2-methoxybenzoyl)benzamide

15 The coupling of Intermediate 8 (0.56 g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.67 g) gave the title compound (0.31 g) as an amorphous solid, mp = 78°.

Analysis Found : C,71.35; H,6.68; N,4.82;.

20 $C_{36}H_{38}N_2O_5 \cdot 1.5H_2O$ Requires : C,71.38; H,6.82; N,4.62%

Example 38

Fumarate of N-[4-[3-methylveratrylamino]propyl]phenyl]-2-indolecarboxamide

25 The coupling of 2-indolecarboxylic acid (0.3 g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.58 g) gave the title compound (0.3 g) as a solid, mp = 196°.

Analysis Found : C, 69.79; H, 6.36; N, 8.21;

$C_{28}H_{31}N_3O_3 \cdot C_4H_4O_4$ Requires : C, 69.88; H, 6.45; N, 8.15%.

Example 39

N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butoxy]phenyl]-6(7)-methyl-2-quinoxalinecarboxamide

The coupling of 6(7)-methyl-2-quinoxalinecarboxylic acid (0.5g) with Intermediate 11(b) (0.94g) gave, after crystallisation from a 1:1 mixture of isopropanol and acetonitrile, the title compound (1.09g) as a solid, mp = 142-148°.

Analysis Found : C, 70.86; H, 6.49; N, 10.40;

$C_{31}H_{34}N_4O_4$ Requires : C, 70.70; H, 6.51; N, 10.64%.

Example 40

N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butoxy]phenyl]-1-isoquinolinecarboxamide

The coupling of 1-isoquinolinecarboxylic acid (0.5g) with Intermediate 11(b) (0.89g) gave, after crystallisation from methanol, the title compound (0.6g) as a solid, mp = 122-123°.

Analysis Found : C, 72.73; H, 6.62; N, 8.12;

$C_{31}H_{33}N_3O_4$ Requires : C, 72.78; H, 6.50; N, 8.21%.

Example 41

N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butoxy]phenyl]-2-quinoxalinecarboxamide

The coupling of 2-quinoxalinecarboxylic acid (0.5g) with Intermediate 11(b) (0.89g) gave, after crystallisation from acetonitrile, the title compound (0.97g) as a solid, mp = 141°.

Analysis Found : C, 69.62; H, 6.29; N, 10.93;

C₃₀H₃₂N₄O₄ (0.3H₂O) Requires : C, 69.55; H, 6.34; N, 10.81%.

Example 42

5 N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butoxy]phenyl]-3-ethoxy-2-quinoxalinecarboxamide

The coupling of 3-ethoxy-2-quinoxalinecarboxylic acid (0.5g) with Intermediate 11(b) (0.63g) gave, after crystallisation from ethanol, the title compound (0.48g) as a solid, mp = 182°.

Analysis Found : C, 72.08; H, 4.51; N, 16.86;

10 C₁₈H₁₁N₃O Requires : C, 72.28; H, 4.45; N, 16.86%.

Example 43

N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butoxy]phenyl]-4-[2-(4-chlorophenyl)-3-trifluoromethylpyrazole]carboxamide

15 The coupling of 2-(4-chlorophenyl)-3-trifluoromethylpyrazole-4-carboxylic acid (1g) with Intermediate 11(b) (1.3g) gave the title compound (1.8g), mp = 153°.

Analysis Found : C, 60.87; H, 5.11; N, 8.77;

C₃₂H₃₂ClF₃N₄O₄ Requires: C, 61.10; H, 5.13; N, 8.91%.

Example 44

20 N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butoxy]phenyl]-5-[4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole]carboxamide

The coupling of 4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole-5-carboxylic acid (1g) with Intermediate 11(b) (1g) gave, after crystallisation from methanol/ethanol (1:1), the title compound (0.7g), mp = 160-180°.

Analysis

Found : C,62.95; H,5.33; F,9.06; N,6.52;

 $C_{33}H_{34}F_3N_3O_4S$

Requires : C,63.35; H,5.48; F,9.11; N,6.72%.

Example 45

N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]phenyl]-2-[5-(2-pyridyl)thiophene]carboxamide

The coupling of 5-(2-pyridyl)thiophene-2-carboxylic acid (1g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623) (1.3g) gave, after crystallisation from methanol, the title compound (1.5g), mp = 196°.

Analysis

Found : C,67.96; H,5.88; N,7.86;

 $C_{30}H_{31}N_3O_4S$

Requires : C,68.03; H,5.90; N,7.93%.

Example 46

N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]phenyl]-4-[2-(3-pyridyl)thiazole]carboxamide

The coupling of 2-(3-pyridyl)thiazole-4-carboxylic acid (1g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623) gave, after crystallisation from isopropanol/methanol, the title compound (1.2g), mp = 125°.

Analysis

Found : C,65.30; H,5.11; N, 10.32;

 $C_{29}H_{30}N_4O_4S$

Requires : C,65.64; H,5.70; N,10.56%

Example 47

N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]phenyl]-5-(4-methyl-2-phenyl-1,2,3-triazole)carboxamide

The coupling of 4-methyl-2-phenyl-1,2,3-triazole-5-carboxylic acid (1g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propoxy]benzenamine

(Intermediate 2(a) in EP-A-494623) (1.6g) gave, after crystallisation from methanol/pyridine (5:1) the title compound (1.6g), mp = 146°.

Analysis Found : C, 67.28; H, 6.10; N, 13.20;

C₃₀H₃₃N₅O₄ (0.5H₂O) Requires : C, 67.14; H, 6.38; N, 13.05%.

5 Example 48

N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-2-hydroxypropoxy]phenyl]-2-quinoxalinecarboxamide

The coupling of 2-quinoxalinecarboxylic acid (0.5g) with Intermediate 13 (1g) gave the title compound (0.9g) as a solid, mp = 158-160°.

10 Analysis Found : C, 65.68; H, 5.99; N, 10.23;

C₂₉H₃₀N₄O₅ (1 H₂O) Requires : C, 65.40; H, 6.05; N, 10.52%.

Example 49

N-[4-(2-(Methylveratrylamino)ethyl)phenyl]-2-(4-methoxyphenyl)-4-quinolinecarboxamide

15 The coupling of 2-(4-methoxyphenyl)-4-quinolinecarboxylic acid (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzeneethanamine (Intermediate 33(b) in EP-A-494623) (0.86g) gave, after crystallisation from ethanol, the title compound as a solid (0.33g), mp = 114°.

Analysis Found : C, 74.72; H, 6.29; N, 7.29;

20 C₃₅H₃₅N₃O₄ Requires : C, 74.84; H, 6.28; N, 7.48%.

Example 50

N-[4-(3-(Methylveratrylamino)propyl)phenyl]-2-(3-methoxyphenyl)-4-quinolinecarboxamide

25 The coupling of 2-(3-methoxyphenyl)-4-quinolinecarboxylic acid (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine

(Intermediate 33(f) in EP-A-494623) (0.9g) gave, after crystallisation from isopropanol, the title compound as a solid (0.51g), mp = 110°.

Analysis Found : C, 75.10; H, 6.52; N, 7.26;

C₃₆H₃₇N₃O₄ Requires : C, 75.10; H, 6.48; N, 7.30%.

5 Example 51

N-[4-[2-(Methylveratrylamino)ethyl]phenyl]-9-oxo-4-thioxanthenecarboxamide

A mixture of 9-oxo-4-thioxanthenecarboxylic acid* (0.8g) and 1-hydroxybenzotriazole (0.42g) in DMF (20 ml) was stirred at room temperature for 10 min. 4-Amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenemethanamine (Intermediate 33(b) in EP-A-494623) (0.94g) in DMF (20 ml) was then added, followed by dicyclohexylcarbodiimide (0.64g) and the mixture was stirred at room temperature for 16 h and then filtered. The filtrate was concentrated in vacuo, treated with dilute sodium hydroxide solution and extracted with dichloromethane. The combined dried organic extracts were evaporated to leave an oil which was purified by column chromatography eluting with dichloromethane : methanol (95:5). The resulting solid was recrystallised from acetonitrile and filtered off to give the title compound as a solid (0.26g), mp = 180°.

Analysis Found : C, 71.02; H, 5.59; N, 5.18; S, 5.78;

20 C₃₂H₃₀N₂O₄S₁ Requires : C, 71.35; H, 5.61; N, 5.20; S, 5.95%.

*Chem. Abstracts 99,5518d.

The following examples were prepared in a similar manner:

Example 52

25 N-[4-(3-(Methylveratrylamino)propyl)phenyl]-5-methoxy-9-oxo-4-thioxanthenecarboxamide

The coupling of 5-methoxy-9-oxo-4-thioxanthenecarboxylic acid* (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine

(Intermediate 33(f) in EP-A-494623) (0.88g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.12g), mp = 144 - 146°.

Analysis Found : C, 69.49; H, 5.86; N, 4.75; S, 5.33;

C₃₄H₃₄N₂O₅S₁ Requires : C, 70.08; H, 5.88; N, 4.81; S, 5.50%.

- 5 *prepared from 2-(methoxyphenylthio)isophthalic acid** in sulphuric acid, mp > 200°, IR includes peaks at 1660cm⁻¹(CO) and 1700cm⁻¹(CO₂H), by a method analogous to that described in Chem. Abstracts 99, 5518d.

- 10 **prepared from 2-iodorsophthalic acid and 2-methoxythiophenol, mp = 208°, IR includes a broad band at 1700-1720cm⁻¹ (CO₂H), by a method analogous to that described in Chem. Abstracts 99, 5518d.

Example 53

N-[4-(2-(Methylveratrylamino)ethyl)phenyl]-5-methoxy-9-oxo-4-thioxanthenecarboxamide

- 15 The coupling of 5-methoxy-9-oxo-4-thioxanthenecarboxylic acid (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzeneethanamine (Intermediate 33(b) in EP-A-494623) (0.8g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.1g) mp = 151°.

Analysis Found : C, 67.98; H, 5.66; N, 4.79; S, 5.29;

C₃₃H₃₂N₂O₅S₁.H₂O Requires : C, 67.55; H, 5.84; N, 4.77; S, 5.46%.

- 20 Example 54

N-[4-(3-(Methylveratrylamino)propoxy)phenyl]-9-oxo-4-thioxanthenecarboxamide

- 25 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzeneethanamine (Intermediate 33(b) in EP-A-494623) (1g) gave, after crystallisation from ethanol, the title compound as a solid (0.47g), mp = 184°.

Analysis Found : C, 69.67; H, 5.68; N, 4.93; S, 5.52;
 $C_{33}H_{32}N_2O_5S_1$ Requires : C, 69.69; H, 5.67; N, 4.93; S, 5.64%.

Example 55

5 N-[4-(2-(Methylveratrylamino)ethyl)phenyl]-7-fluoro-9-oxo-4-thioxanthenecarboxamide

The coupling of 7-fluoro-9-oxo-4-thioxanthenecarboxylic acid* (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzeneethanamine (Intermediate 33(b) in EP-A-494623) (0.87g) gave, after crystallisation from ethanol, the title compound as a solid (0.3g), mp = 205°.

10 Analysis Found : C, 68.99; H, 5.23; F, 3.31; N, 4.99; S, 5.58;

$C_{32}H_{29}F_1N_2O_4S_1$ Requires : C, 69.04; H, 5.25; F, 3.41; N, 5.03; S, 5.76%.

15 *prepared from 2-(4-fluorophenylthio)isophthalic acid** in sulphuric acid, mp>200°, IR includes peaks at 1660cm⁻¹ (CO) and 1700cm⁻¹ (CO₂H), by a method analogous to that described in Chem. Abstracts 99, 5518d.

**prepared from 2-iodoisophthalic acid and 4-fluorothiophenol, mp = 204-205°, IR includes a large band at 1700cm⁻¹ (CO₂H).

Example 56

20 N-[4-(3-(Methylveratrylamino)propyl)phenyl]-7-fluoro-9-oxo-4-thioxanthenecarboxamide

25 The coupling of 7-fluoro-9-oxo-4-thioxanthenecarboxylic acid (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.9g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.3g) mp = 160°.

Analysis Found : C, 69.24; H, 5.46; F, 3.20; N, 4.85;
S, 5.49;

$C_{33}H_{31}F_1N_2O_4S_1$ Requires : C, 69.45; H, 5.48; F, 3.33; N, 4.91;
S, 5.62%.

5 Example 57

N-[4-(4-(Methylveratrylamino)butyl)phenyl]-7-fluoro-9-oxo-4-thioxanthenecarboxamide

10 The coupling of 7-fluoro-9-oxo-4-thioxanthenecarboxylic acid (0.4g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenebutanamine (Intermediate 33(a) in EP-A-494623) (0.48g) gave, after crystallisation from ethanol the title compound as a solid (0.076g), mp = 168°.

Analysis Found : C, 69.80; H, 5.77; F, 3.24; N, 4.66;
S, 5.42;

15 $C_{34}H_{33}F_1N_2O_4S_1$ Requires : C, 69.84; H, 5.69; F, 3.25; N, 4.79;
S, 5.48%.

Example 58

N-[4-(3-(Methylveratrylamino)propylthio)phenyl]-9-oxo-4-thioxanthenecarboxamide

20 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with N-[3-[(4-aminophenyl)thio]propyl]-3,4-dimethoxy-N-methylbenzenemethanamine (Intermediate 38(d) in EP-A-494623) (1g) gave, after crystallisation from ethanol, the title compound as a solid (0.1g), mp = 148°.

Analysis Found : C, 67.73; H, 5.35; N, 4.71; S, 10.85;

$C_{33}H_{32}N_2O_4S_2$ Requires : C, 67.78; H, 5.52; N, 4.79; S, 10.96%.

Example 59N-[4-(Methylveratrylamino)methyl]phenyl]-9-oxo-4-thioxanthenecarboxamide

5 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with Intermediate 11(d) (0.9g) gave, after crystallisation from ethanol, the title compound as a solid (0.1g), mp = 166°.

Analysis Found : C, 70.85; H, 5.38; N, 5.50; S, 5.90;

C₃₁H₂₈N₂O₄S₁ Requires : C, 70.97; H, 5.38; N, 5.34; S, 6.11%.

Example 60

10 N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-9-oxo-4-thioxanthenecarboxamide

The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623) (1.14g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.35g), mp = 210°.

15 Analysis Found : C, 70.29; H, 5.51; N, 4.89; S, 5.52;

C₃₄H₃₂N₂O₅S₁ Requires : C, 70.32; H, 5.55; N, 4.83; S, 5.52%.

Example 61

20 N-[4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-5-methoxy-9-oxo-4-thioxanthenecarboxamide

The coupling of 5-methoxy-9-oxo-4-thioxanthenecarboxylic acid (3g) with 4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]benzenamine (Intermediate 2(c) in EP-A-494623) (3g) gave, after crystallisation from methanol, the title compound as a solid (1.38g), mp = 218 - 219°.

NMR includes signals at δ 2.8(4H,m,N-(CH₂)₂-Ph);

25 3.7(6H,s,2OCH₃); 3.8(3H,s,OCH₃).

Example 62N-[4-(2-(Methylhomoveratrylamino)ethoxy)phenyl]-9-oxo-4-xanthenecarboxamide

5 The coupling of 9-oxo-4-xanthenecarboxylic acid (0.33g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzeneethanamine (Intermediate 36(a) in EP-A-494623) (0.45g) gave, after crystallisation from ethanol, the title compound as a solid (0.15g), mp = 152°.

Analysis

Found : C, 71.54; H, 5.85; N, 5.07;

 $C_{33}H_{32}N_2O_6$

Requires : C, 71.72; H, 5.84; N, 5.07%.

10 Example 63N-[4-(2-(Methylhomoveratrylamino)ethoxy)phenyl]-9-oxo-4-thioxanthenecarboxamide

15 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzeneethanamine (Intermediate 36(a) in EP-A-494623) (1g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.35g), mp = 168°.

Analysis

Found : C, 69.71; H, 5.67; N, 4.91; S, 5.50;

 $C_{33}H_{32}N_2O_5S_1$

Requires : C, 69.69; H, 5.67; N, 4.93; S, 5.64%.

Example 6420 N-[4-(2-(Methylveratrylamino)ethoxy)phenyl]-9-oxo-4-thioxanthenecarboxamide

25 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (1g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzenemethanamine (Intermediate 36(b) in EP-A-494623) (1.23g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.2g), mp = 188°.

Analysis Found : C, 68.89; H, 5.75; N, 5.50; S, 5.46;

$C_{32}H_{30}N_2O_5S_1$ Requires : C, 69.29; H, 5.45; N, 5.05; S, 5.78%.

Example 65

5 N-[4-(3-(Methylhomoveratrylamino)propoxy)phenyl]-9-oxo-4-thioxanthenecarboxamide

The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with N-[3-(4-aminophenoxy)propyl]-3,4-dimethoxy-N-methylbenzeneethanamine (Intermediate 38(a) in EP-A-494623) (1g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.6g), mp = 174°.

10 Analysis Found : C, 69.70; H, 5.89; N, 4.70; S, 5.39;

$C_{34}H_{34}N_2O_5S_1$ Requires : C, 70.08; H, 5.88; N, 4.81; S, 5.50%.

Example 66

N-[4-(4-(Methylveratrylamino)butyl)phenyl]-9-oxo-4-thioxanthenecarboxamide

15 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.77g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenebutanamine (Intermediate 33(a) in EP-A-494623) (0.98g) gave, after crystallisation from ethanol, the title compound as a solid (0.27g), mp = 156°.

Analysis Found : C, 71.82; H, 6.00; N, 5.06; S, 5.63;

$C_{34}H_{34}N_2O_4S_1$ Requires : C, 72.05; H, 6.05; N, 4.94; S, 5.66%.

20 Example 67

N-[4-(4-(Methylhomoveratrylamino)butyl)phenyl]-7-fluoro-9-oxo-4-thioxanthenecarboxamide

25 The coupling of 7-fluoro-9-oxo-4-thioxanthenecarboxylic acid (1g) with 4-amino-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylbenzenebutanamine (Intermediate 33(c) in EP-A-494623) (1.25g) gave, after crystallisation from ethanol, the title compound as a solid (0.95g), mp = 145°.

Analysis Found : C, 69.87; H, 5.79; F, 2.95; N, 4.30;
S, 5.35;

$C_{35}H_{35}F_1N_2O_4S_1$ Requires : C, 70.21; H, 5.89; F, 3.17; N, 4.68;
S, 5.35%.

5 Example 68

N-[4-(2-(Methylhomoveratrylamino)ethoxy)phenyl]-7-fluoro-9-oxo-4-thioxanthenecarboxamide

10 The coupling of 7-fluoro-9-oxo-4-thioxanthenecarboxylic acid (1g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzeneethanamine (Intermediate 36(a) in EP-A-494623) (1.2g) gave, after crystallisation from ethanol, the title compound as a solid (0.72g), mp = 145°.

Analysis Found : C, 67.42; H, 5.26; F, 2.92; N, 4.92;
S, 5.85;

15 $C_{33}H_{31}F_1N_2O_5S_1$ Requires : C, 67.56; H, 5.33; F, 3.24; N, 4.77;
S, 5.46%.

Example 69

N-[4-(2-(Methyveratrylamino)ethoxy)phenyl]-9-oxo-4-xanthenecarboxamide

20 The coupling of 9-oxo-4-xanthenecarboxylic acid (0.6g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzenemethanamine (Intermediate 36(b) in EP-A-494623) (0.79g) gave, after crystallisation from ethanol, the title compound as a solid (0.21g), mp = 110°.

Analysis Found : C, 71.17; H, 5.59; N, 5.29;

$C_{32}H_{30}N_2O_6$ Requires : C, 71.36; H, 5.62; N, 5.20%.

Example 70N-[4-(2-(Methylhomoveratrylamino)ethyl)phenyl]-9-oxo-4-thioxanthenecarboxamide

5 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with 4-amino-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylbenzeneethanamine (Intermediate 33(e) in EP-A-494623) (1g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.43g), mp = 154°.

Analysis Found : C, 71.83; H, 5.92; N, 5.08; S, 5.89;

C₃₃H₃₂N₂O₄S₁ Requires : C, 71.71; H, 5.84; N, 5.07; S, 5.80%.

10 Example 71N-[4-(4-(Methylhomoveratrylamino)butyl)phenyl]-9-oxo-4-xanthenecarboxamide

15 The coupling of 9-oxo-4-xanthenecarboxylic acid (0.3g) with 4-amino-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylbenzenebutanamine (Intermediate 33(c) in EP-A-494623) (0.42g) gave, after crystallisation from ethanol, the title compound as a solid (0.09g), mp = 102°.

Analysis Found : C, 73.58; H, 6.36; N, 5.07;

C₃₅H₃₆N₂O₅ Requires : C, 74.44; H, 6.43; N, 4.96%.

Example 7220 N-[4-(3-(Methylhomoveratrylamino)propoxy)phenyl]-9-oxo-4-xanthenecarboxamide

The coupling of 9-oxo-4-xanthenecarboxylic acid (0.6g) with N-[3-(4-aminophenoxy)propyl]-3,4-dimethoxy-N-methylbenzeneethanamine Intermediate 38(a) in EP-A-494623) (1.04g) gave, after crystallisation from ethanol, the title compound as a solid (0.26g), mp = 126°.

25

Analysis Found : C, 71.27; H, 6.06; N, 4.84;

C₃₄H₃₄N₂O₆ Requires : C, 72.07; H, 6.05; N, 4.94%.

Example 73

N-[4-[4-[(4-Methylthiobenzyl)methylamino]butyl]phenyl]-9-oxo-4-
5 thioxanthenecarboxamide

The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with 4-amino-N-[[4-(methylthio)phenyl]methyl]-N-methylbenzenebutanamine (Intermediate 33(j) in EP-A-494623) (1g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.39g), mp = 167°.

10 Analysis Found : C, 71.47; H, 5.78; N, 5.13; S, 11.50;

C₃₃H₃₂N₂O₂S₂ Requires : C, 71.70; H, 5.84; N, 5.07; S, 11.60%.

Example 74

N-[4-[3-[(4-Methoxybenzyl)methylamino]propyl]phenyl]-9-oxo-4-
15 thioxanthenecarboxamide

The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.77g) with 4-amino-N-[(4-methoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(g) in EP-A-494623) (0.85g) gave, after crystallisation from ethanol, the title compound as a solid (0.34g), mp = 170°.

Analysis Found : C, 73.22; H, 5.84; N, 5.35; S, 5.89;

20 C₃₂H₃₀N₂O₃S₁ Requires : C, 73.53; H, 5.78; N, 5.36; S, 6.13%.

Example 75

N-[4-(3-(Methylhomoveratrylamino)propyl)phenyl]-9-oxo-4-
25 thioxanthenecarboxamide

The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.8g) with 4-amino-N-[2-(3,4-dimethoxyphenyl)ethyl]-N-methylbenzenepropanamine (Intermediate 33(d)

in EP-A-494623) (1g) gave, after crystallisation from acetonitrile, the title compound as a solid (0.35g), mp = 143°.

Analysis Found : C, 72.10; H, 5.91; N, 4.70; S, 5.48;

C₃₄H₃₄N₂O₄S₁ Requires : C, 72.06; H, 6.05; N, 4.94; S, 5.66%.

5 Example 76

N-[4-[2-[(4-Methoxyphenethyl)methylamino]ethyl]phenyl]-9-oxo-4-thioxanthenecarboxamide

10 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.4g) with 4-amino-N-[2-(4-methoxyphenyl)ethyl]-N-methylbenzeneethanamine (Intermediate 33(k) in EP-A-494623) (0.44g) gave, after crystallisation from ethanol, the title compound as a solid (0.13g), mp = 163°.

Analysis Found : C, 72.49; H, 5.80; N, 5.35; S, 5.97;

C₃₂H₃₀N₂O₃S₁ Requires : C, 73.53; H, 5.79; N, 5.36; S, 6.13%.

Example 77

15 N-[4-(5-(Methylveratrylamino)pentyl)phenyl]-9-oxo-4-thioxanthenecarboxamide

The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.4g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepentanamine (Intermediate 33(l) in EP-A-494623) (0.53g) gave, after crystallisation from ethanol, the title compound as a solid (0.2g), mp = 166°.

20 Analysis Found : C, 72.31; H, 6.22; N, 4.85; S, 5.39;

C₃₅H₃₆N₂O₄S₁ Requires : C, 72.38; H, 6.25; N, 4.82; S, 5.52%.

Example 78

N-[4-(3-(Methylveratrylamino)propyl)phenyl]-9-oxo-4-thioxanthenecarboxamide

25 The coupling of 9-oxo-4-thioxanthenecarboxylic acid (3g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in

EP-A-494623) (3.7g) gave, after crystallisation from ethanol, the title compound as a solid (2.5g), mp = 150°.

Analysis Found : C, 71.70; H, 5.88; N, 5.06; S, 5.72;

C₃₃H₃₂N₂O₄S₁ Requires : C, 71.71; H, 5.84; N, 5.07; S, 5.80%.

5 Example 79

N-[4-[3-(Methylveratrylamino)propyl]phenyl]-9-fluorenone-4-carboxamide

The coupling of 9-fluorenone-4-carboxylic acid (0.5g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.63g) gave, after crystallisation from ethanol, the title compound (0.75g) as a solid, mp = 50 - 75°.

Analysis Found : C, 75.12; H, 6.38; N, 5.23;

C₃₃H₃₂N₂O₄ (0.4H₂O) Requires : C, 75.09; H, 6.26; N, 5.23%.

Example 80

15 Fumarate of N-[4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propylthio]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (0.5 g) with 4-[[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)propyl]thio]benzenamine (Intermediate 2(b) in EP-A-494623) (0.79 g) gave the title compound (0.4 g) as a solid, mp : 192°.

Analysis Found : C, 66.94; H, 5.68; N, 4.07;

20 C₃₄H₃₄N₂O₄S.C₄H₄O Requires : C, 66.85; H, 5.61; N, 4.10%.

Example 81

Oxalate of N-[4-[3-(methylveratrylamino)propoxy]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (0.8g) with N-[3-(4-aminophenoxy)propyl]-3,4-dimethoxy-N-methylbenzenemethanamine

(Intermediate 38(c) in EP-A-494623) (1.17g) gave the title compound (1.2g) as a solid, mp : 168°.

Analysis

Found : C,66.92; H,5.79; N,4.42;

$C_{33}H_{34}N_2O_5 \cdot C_2H_2O_4$

Requires : C,66.87; H,5.77; N,4.46%.

5 Example 82

Fumarate of N-[4-[4-(methyilveratrylamino)]butyl]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenebutanamine (Intermediate 33(a) in EP-A-494623) (1.16 g) gave the title compound (1.2g) as a solid, mp : 182°.

10 Analysis

Found : C,70.06; H,6.19; N,4.22;

$C_{34}H_{36}N_2O_4 \cdot C_4H_4O_4$

Requires : C,69.92; H,6.18; N,4.29%.

Example 83

N-[4-[2-(Methyilveratrylamino)ethyl]phenyl]-3-benzoylbenzamide

15 The coupling of 3-benzoylbenzoic acid (0.22g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzeneethanamine (Intermediate 33(b) in EP-A-494623) (0.3g) gave, after crystallisation from diisopropyl ether, the title compound (0.28g) as a solid, mp : 130°.

Analysis

Found : C,75.19; H,6.37; N,5.50;

$C_{32}H_{32}N_2O_4$

Requires : C,75.57; H,6.34; N,5.51%.

20 Example 84

Fumarate of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]phenyl]-3-benzoylbenzamide

25 The coupling of 3-benzoylbenzoic acid (0.8g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (1.2g) gave the title compound (0.3g) as a solid, mp : 198°.

Analysis Found : C,70.36; H,6.03; N,4.08;

$C_{35}H_{36}N_2O_4 \cdot C_4H_4O_4$ Requires : C,70.46; H,6.06; N,4.21%.

Example 85

5 N-[4-[3-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (1g) with 4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]benzenamine (Intermediate 2(a) in EP-A-494623) (1.5g) gave, after crystallisation from isopropanol, the title compound (1.3g) as a solid, mp : $>260^\circ$.

10 Analysis Found : C,74.12; H,6.18; N,5.16;

$C_{34}H_{34}N_2O_5$ Requires : C,74.15; H,6.22; N,5.08%.

Example 86

Oxalate of N-[2-methoxy-4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-3-benzoylbenzamide

15 The coupling of 3-benzoylbenzoic acid (0.6g) with Intermediate 11(a) (0.98g) gave the title compound (1g) as a solid, mp : 158° .

Analysis Found : C,66.29; H,5.72; N,4.10;

$C_{35}H_{36}N_2O_6 \cdot C_2H_2O_4$ Requires : C,66.26; H,5.71; N,4.18%.

Example 87

20 Fumarate of N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (0.6g) with 4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]benzenamine (Intermediate 2(c) in EP-A-494623) (0.82g) gave the title compound (1g) as a solid, mp : 134° .

Analysis Found : C,70.87; H,5.84; N,4.33;

$C_{33}H_{32}N_2O_4 \cdot 1/2 C_4H_4O_4 \cdot 1.5 H_2O$ Requires : C,70.98; H,6.04; N,4.73%.

Example 88

5 Oxalate of N-[2-methyl-4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (0.86g) with 2-methyl-4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]benzenamine (Intermediate 16(c) in EP-A-494623) (1.25g) gave the title compound (0.6g) as a solid, mp : 230°.

Analysis Found : C,72.19; H,6.06; N,4.54;

10 $C_{34}H_{34}N_2O_4 \cdot 1/2 C_2H_2O_4$ Requires : C,72.51; H,6.08; N,4.83%.

Example 89

Fumarate of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-3-(3-methoxybenzoyl)benzamide

15 The coupling of Intermediate 14 (0.5g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.63g) gave, the title compound (0.7g) as a solid, mp : 188°.

Analysis Found : C,69.13; H,6.04; N,4.13;

$C_{36}H_{38}N_2O_5 \cdot C_4H_4O_4$ Requires : C,69.15; H,6.09; N,4.03%.

Example 90

20 Fumarate of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-3-(4-fluorobenzoyl)benzamide

The coupling of Intermediate 15 (0.46g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.64g) gave, the title compound (0.25g) as a solid, mp : 176°.

Analysis

Found : C,68.51; H,5.85; F,2.86; N,4.31;

 $C_{35}H_{35}FN_2O_4 \cdot C_4H_4O_4$ Requires : C,68.61; H,5.76; F,2.78; N,4.10%.Example 915 Fumarate of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]phenyl]-3-(4-methoxybenzoyl)benzamide

The coupling of 3-(4-methoxybenzoyl)benzoic acid* (0.4g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.53g) gave the title compound (0.55g) as a solid, mp : 178°.

Analysis

Found : C,68.85; H,6.01; N,4.12;

10 $C_{36}H_{38}N_2O_5 \cdot C_4H_4O_4$ Requires : C,69.15; H,6.09; N,4.03%.

* A.I. Meyers et al., J.Amer. Chem. Soc., 91 (21), 5886-87 (1969).

Example 92Oxalate of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]phenyl]-5-(3-fluorobenzoyl)-2-methoxy-benzamide15

The coupling of Intermediate 20 (0.5g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.62g) gave, the title compound (0.6g) as a solid, mp : 112°.

Analysis

Found : C,66.23; H,5.73; F,2.85; N,4.02;

 $C_{36}H_{37}FN_2O_5 \cdot C_2H_2O_4$ Requires : C,66.46; H,5.72; F,2.77; N,4.08%.20 Example 93Oxalate of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]phenyl]-5-benzoyl-2-methoxybenzamide25

The coupling of Intermediate 22 (0.5g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)]butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.66g) gave the title compound (1g) as a solid, mp : 202°.

Analysis Found : C,68.16; H,6.04; N,4.13;

$C_{36}H_{38}N_2O_5 \cdot C_2H_2O_4$ Requires : C,68.25; H,6.03; N,4.19%.

Example 94

5 Oxalate of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-5-(3-methoxybenzoyl)-2-methoxybenzamide

The coupling of Intermediate 24 (0.5g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.59g) gave the title compound (0.8 g) as a solid, mp : 116°.

Analysis Found : C,65.24; H,6.18; N,3.81;

10 $C_{37}H_{40}N_2O_6 \cdot C_2H_2O_4 \cdot 1H_2O$ Requires : C,65.35; H,6.18; N,3.90%.

Example 95

Oxalate of N-[4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-5-(3-methylbenzoyl)-2-methoxybenzamide

15 The coupling of 5-(3-methylbenzoyl)-2-methoxybenzoic acid* (0.42g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.53g) gave the title compound (0.45g) as a solid, mp : 114°.

Analysis Found : C,67.56; H,6.34; N,3.89;

$C_{37}H_{40}N_2O_5 \cdot C_2H_2O_4 \cdot 1/2H_2O$ Requires : C,67.71; H,6.26; N,4.04%.

20 * Fujii Yasao et al., Nippon Noyaku Gakkaishi, 4 (4), 511-514 (1979).

Example 96

Fumarate of N-[2-methyl-4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-3-benzoylbenzamide

25 The coupling of 3-benzoylbenzoic acid (1g) with Intermediate 11(c) (1.4g) gave the title compound (0.9g) as a solid, mp = 94°.

Analysis

Found : C,65.30; H, 6.16; N, 4.13;

 $C_{35}H_{36}N_2O_5 \cdot C_4H_4O_4 \cdot 2 H_2O$ Requires : C, 65.35; H, 6.18; N, 3.90%.Example 975 N-[4-(4-((4-Fluorobenzyl)methylamino)butyl)phenyl]-9-oxo-4-thioxanthenecarboxamide

The coupling of 9-oxo-4-thioxanthenecarboxylic acid (0.72g) with 4-amino-N-[(4-fluorophenyl)methyl]-N-methylbenzenebutanamine (Intermediate 33(i) in EP-A-494623) (0.86g) gave, after crystallisation from ethanol, the title compound as a solid (0.37g), mp = 168°.

10 Analysis

Found : C,72.54; H,5.57; F,3.62; N,5.92; S,5.76;

 $C_{32}H_{29}F_1N_2O_2S_1$
S,6.11%.

Requires : C,73.26; H,5.57; F,3.62; N,5.34;

Example 9815 N-[2-Methyl-4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)propoxy]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (1g) with Intermediate 11(c) (1.46g) gave the title compound as an oil (0.86g), fumarate (from isopropanol), mp = 94°.

Analysis

Found : C,65.30; H,6.16; N,4.13;

 $C_{35}H_{36}N_2O_5 \cdot C_4H_4O_4 \cdot 2H_2O$ Requires : C,65.34; H,6.18; N,3.90%.20 Example 99Fumarate of N-[4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-2-hydroxypropoxy]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (0.5g) with Intermediate 13 (0.79g) gave the title compound (0.7g) as a solid, mp = 160°.

Analysis Found : C,66.92; H,5.57; N,4.05;

$C_{34}H_{34}N_2O_6$ $C_4H_4O_4$ Requires : C,66.85; H,5.61; N,4.10%.

Example 100

5 Fumarate of N-[4-[3-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-2-hydroxypropoxy]phenyl]-3-(4-fluorobenzoyl)benzamide

The coupling of Intermediate 15 (0.36g) with Intermediate 13 (0.44g) gave the title compound (0.2g) as a solid, mp = 162 - 164°.

Analysis Found : C,65.15; H,5.41; F,2.65; N,4.05;

$C_{34}H_{33}FN_2O_6$ $C_4H_4O_4$ Requires : C,65.14; H,5.32; F,2.71; N,4.00%.

10 Example 101

Oxalate of N-[4-[3-(methylbenzylamino)propoxy]phenyl]-3-benzoylbenzamide

The coupling of 3-benzoylbenzoic acid (0.7g) with Intermediate 11(e) (0.83g) gave the title compound (1.1g) as a solid, mp = 172°.

Analysis Found : C,69.92; H,5.69; N,4.94;

15 $C_{31}H_{30}N_2O_3$ $C_2H_2O_4$ Requires : C,69.71; H,5.67; N,4.93%.

Example 102

Oxalate of N-[4-[3-(1,2,3,4-tetrahydro-2-isoquinolinyl)propoxy]phenyl]-3-benzoylbenzamide

20 The coupling of 3-benzoylbenzoic acid (0.4g) with 4-[3-(1,2,3,4-tetrahydro-2-isoquinolinyl)propoxy]benzenamine (Intermediate 88 in EP-A-494623) (0.5g) gave the title compound (0.37g) as a solid, mp = 180°.

Analysis Found : C,70.21; H,5.57; N,4.88;

$C_{32}H_{30}N_2O_3$ $C_2H_2O_4$ Requires : C,70.33; H,5.56; N,4.82%.

Example 103N-[4-(2-(Benzylmethylamino)ethoxy)phenyl]-3-benzoylbenamide

5 The coupling of 3-benzoylbenzoic acid (0.8g) with Intermediate 19 (0.9g) gave the title compound as an oil (1.1g), hydrochloride (from diethyl ether), mp = 140°.

Analysis Found : C,71.35; H,5.85; Cl,6.91; N,5.43;

C₃₀H₂₇N₂O₃, HCl Requires : C,71.92; H,5.83; Cl, 7.08;

Example 104

10 N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide

A mixture of 4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid* (1g) and 1-hydroxybenzotriazole (0.58g) in DMF (50ml) was stirred at room temperature for 10 min. 4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (1.1g) was
15 then added, followed by dicyclohexylcarbodiimide (0.67g) and the mixture was stirred at room temperature for 16 h and then filtered. The filtrate was concentrated in vacuo, treated with dilute sodium hydroxide solution and extracted with methylene chloride. The combined, dried, organic extracts were evaporated and the residue was purified by column chromatography on silica gel
20 eluting with methylene chloride/methanol (99:1) to give the title compound (0.6g) as a white solid, after crystallisation from ethyl acetate, mp = 117-120°.

Analysis Found: C,74.40; H,6.22; N,4.63; O,14.49;

C₃₇H₃₆N₂O₅ 0.5H₂O Requires: C,74.35; H,6.24; N,4.68; O,14.72%

*Paolo Da Re E. Sianesi and V. Mancini, Chem. Ber., 1966, 99, 1962.

25 The following compounds were prepared in a similar manner:

Example 105N-[4-(3-(Methylveratrylamino)propylthio)phenyl]-1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxamide

5 The coupling of 1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxylic acid* (0.68g) with N-[3-[(4-aminophenyl)thio]propyl]-3,4-dimethoxy-N-methylbenzenemethanamine (Intermediate 38(d) in EP-A-494623) (0.88g) gave, after crystallisation from isopropanol, the title compound as a solid (0.1g), mp = 130°.

Analysis

Found : C, 70.89; H, 6.08; N, 6.98; S, 5.50;

10 $C_{35}H_{35}N_3O_4S_1$

Requires : C, 70.80; H, 5.94; N, 7.08; S, 5.40%.

*Graham J Atwell et al., J.Med.Chem. 1989, 32, 396-401.Example 106N-[4-(3-(Methylveratrylamino)propyl)phenyl]-1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxamide

15 The coupling of 1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxylic acid (0.89g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenepropanamine (Intermediate 33(f) in EP-A-494623) (0.9g) gave, after crystallisation from isopropanol, the title compound as a solid (0.47g), mp = 180°.

Analysis

Found : C, 74.73; H, 6.28; N, 7.39;

20 $C_{35}H_{35}N_3O_4$

Requires : C, 74.84; H, 6.28; N, 7.48%.

Example 107N-[4-(2-(Methylveratrylamino)ethoxy)phenyl]-1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxamide

25 The coupling of 1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxylic acid (0.8g) with N-[2-(4-aminophenoxy)ethyl]-3,4-dimethoxy-N-methylbenzenemethanamine

(Intermediate 36(b) in EP-A-494623) (0.95g) gave, after crystallisation from ethanol, the title compound as a solid (0.6g), mp = 175°.

Analysis Found : C, 72.50; H, 5.82; N, 7.45;

C₃₄H₃₃N₃O₅ Requires : C, 72.45; H, 5.90; N, 7.45%.

5 Example 108

N-[4-(4-(Methylveratrylamino)butyl)phenyl]-1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxamide

10 The coupling of 1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxylic acid (0.8g) with 4-amino-N-[(3,4-dimethoxyphenyl)methyl]-N-methylbenzenebutanamine (Intermediate 33(a) in EP-A-494623) (0.52g) gave, after crystallisation from diisopropyl ether, the title compound as a solid (0.13g), mp = 171°.

Analysis Found : C, 72.11; H, 6.59; N, 6.89;

C₃₆H₃₇N₃O₄ · H₂O Requires : C, 72.76; H, 6.57; N, 7.06%.

Example 109

15 N-[4-[2-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinoliny)ethyl]phenyl]-4-oxo-2-phenyl-4H-1-benzopyran-8-carboxamide

20 The coupling of 4-oxo-2-phenyl-4H-1-benzopyran-8-carboxylic acid (0.5 g) with 4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinoliny)ethyl]benzenamine (Intermediate 2(c) in EP-A-494623) (0.58 g) gave, after crystallisation from acetonitrile, the title compound (0.3 g) as a solid, mp 135-140°.

Analysis Found : C, 73.17; H, 5.78; N, 4.87; O, 16.38;

C₃₅H₃₂N₂O₅ · 0.75H₂O Requires : C, 73.21; H, 5.88; N, 4.85; O, 16.02%.

Example 110N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-2-(3-methoxyphenyl)-4-oxo-4H-1-benzopyran-8-carboxamide

5 The coupling of 2-(3-methoxyphenyl)-4-oxo-4H-1-benzopyran-8-carboxylic acid (0.5g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.52 g) gave, after crystallisation from ethyl acetate, the title compound (0.45 g) as a solid, mp = 152°.

Analysis

Found : C,73.22; H,6.21; N,4.44; O,16.09;

10 $C_{38}H_{38}N_2O_6 \cdot 0.25H_2O$ Requires : C,73.23; H,6.22; N,4.49; O,16.04%.

Example 111N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxamide

15 The coupling of 1,4-dihydro-4-oxo-2-phenyl-8-quinolinecarboxylic acid (0.4 g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.47 g) gave, after crystallisation from isopropanol, the title compound (100 mg) as a solid, mp = 204°.

Analysis

Found : C,75.01; H,6.31; N,7.01; O,11.60;

$C_{37}H_{37}N_3O_4 \cdot 0.25H_2O$ Requires : C,75.04; H,6.38; N,7.09; O,11.48%.

20 Example 112

N-[4-[4-(1,2,3,4-Tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]phenyl]-1,4-dihydro-2-(3-methoxyphenyl)-4-oxo-8-quinolinecarboxamide

25 The coupling of 1,4-dihydro-2-(3-methoxyphenyl)-4-oxo-8-quinolinecarboxylic acid (0.22g) with 4-[4-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)butyl]benzenamine (Intermediate 2(d) in EP-A-494623) (0.25 g) gave, after crystallisation from ethyl acetate, the title compound (50 mg) as a solid, mp = 116°.

Analysis

Found : C,71.32; H,6.45; N,6.63;

 $C_{38}H_{39}N_3O_5 \cdot 1.25H_2O$

Requires : C,71.28; H,6.53; N,6.56%.

Example 113In vitro cytotoxicity of MDR inhibitors in Chinese Hamster Ovary cells

- 5 The multidrug resistant Chinese Hamster Ovary (CHO) cell line $CHRC5$ was obtained from Dr V Ling, Princess Margaret Hospital, Toronto, Canada and maintained as anchorage-dependent monolayers in α -minimum essential medium supplemented with thymidine, adenosine, 10% fetal bovine serum, 2mM L-glutamine (Flow), 100 units/ml penicillin and 100 μ g/ml streptomycin in a
10 humidified atmosphere of 95% air and 5% carbon dioxide. Cells were passaged into culture flasks twice a week after dissociation with EDTA.

- $CHRC5$ cells were seeded at a density of 10^4 cells/well in microtitre plates. After 24 hours, the medium was removed and replaced by 0.1ml of fresh medium containing successive two-fold dilutions of MDR inhibitors. Each MDR
15 inhibitor was assayed in duplicate in two-fold dilution from 1250 to 20nM. The last well of each column was utilised to verify the lack of toxicity at the top dose of the MDR inhibitor in the absence of doxorubicin. Other control conditions were assayed on each microtitre plate : cells alone (1 well), doxorubicin alone (7 wells), amiodarone (a range of two-fold dilutions starting at 5 μ M; two wells
20 each). 0.1ml of a 10 μ g/ml solution of doxorubicin was added. After 72 hours incubation cell viability was assessed by the reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT; Sigma) to a dark blue formazan product. In particular, 20 μ l of a 5mg/ml solution of MTT prepared in phosphate buffered saline was added to each well. After 4 hours incubation at 37°, the
25 medium was aspirated and replaced with 0.1ml dimethylsulphoxide. After vigorous shaking, the quantity of formazan product formed was assessed by its optical density at 550nm. The absorbance is directly related to the number of surviving cells in the wells.

- 30 Cytotoxicity calculations were performed on the average of the two wells for each condition. The concentration of each MDR inhibitor giving a 50%

reduction of the optical density relative to cells treated with doxorubicin alone was determined to give an EC₅₀ value.

Results

5 In the above test the compounds of the specific Examples hereinabove had EC₅₀ values of less than 1 μ M and are therefore more potent than prototype MDR inhibitors including amiodarone (EC₅₀ 3 μ M) and verapamil (3 μ M).

The following are examples of pharmaceutical compositions according to the invention. The term 'Active Ingredient' as used hereinafter means a compound of the invention and may be for example a compound of Examples 1-112.

10 Example A - Oral Tablet

| | <u>Per Tablet (mg)</u> |
|----------------------------|------------------------|
| Active Ingredient | 50.0 |
| Microcrystalline Cellulose | 110.0 |
| Lactose | 67.5 |
| 15 Sodium Starch Glycolate | 20.0 |
| Magnesium Stearate | 2.5 |
| Total | 250.0 |

20 The drug is sieved through a 250 μ m sieve and then the five powders are intimately mixed in a blender and compressed on 3/8 inch standard concave punches in a tableting machine.

Example B - Oral Capsule

| | <u>Per Capsule (mg)</u> |
|----------------------------|-------------------------|
| Active Ingredient | 50.0 |
| Microcrystalline Cellulose | 66.5 |

| | |
|-------------------------|-------|
| Lactose USP | 66.5 |
| Sodium Starch Glycolate | 15.0 |
| Magnesium Stearate | 2.0 |
| Total | 200.0 |

- 5 The drug is sieved through a 250 μ m sieve and then the five powders are intimately mixed in a blender and filled into No. 2 hard gelatin capsule shells on a capsule filling machine.

Example C - Injection for Intravenous Administration (10mg in 10mL)

| | <u>% w/w</u> |
|-----------------------------|--------------|
| 10 Active Ingredient | 0.1 |
| Cancer chemotherapy agent | as required |
| Water for Injection to | 100.0 |
| Dilute hydrochloric acid to | pH 3.0 |

- 15 The active ingredient (and cancer chemotherapy agent where appropriate) is dissolved with mixing in the Water For Injection, adding acid slowly until the pH is 3.0. The solution is sparged with nitrogen and filtratively sterilized through a sterilized filter of 0.22 micron pore size. Under aseptic conditions this sterile solution is placed into sterile ampoules and the ampoules flame sealed.

Example D - Oral Syrup

| | <u>% w/v</u> |
|-----------------------------|--------------|
| 20 Active Ingredient | 2.0 |
| Cancer chemotherapy agent | as required |
| Dilute hydrochloric acid to | pH 3.0 |
| Sorbitol solution | 60 v/v |


| | |
|---------|-------------|
| Flavour | as required |
|---------|-------------|

| | |
|--------------------|-----|
| Distilled water to | 100 |
|--------------------|-----|

- 5 The active ingredient (and cancer chemotherapy agent where appropriate) is dissolved in some of the water with stirring by adding gradually the hydrochloric acid until the pH is 3.0. The sorbitol solution, flavour and the rest of the water are added and the pH re-adjusted to 3.0. The syrup is clarified by filtration through suitable filter pads.

CLAIMS

1. A compound of formula (I):



5

and salts and solvates thereof, including physiologically acceptable salts and solvates thereof, in which:

A represents an oxygen or a sulphur atom, a bond or a group $(\text{CH}_2)_l\text{NR}^7$ (where l represents zero or 1 and R^7 represents a hydrogen atom or a methyl group);

- 10 B represents a C_{1-4} alkylene chain optionally substituted by a hydroxyl group, except that the hydroxyl group and moiety A cannot be attached to the same carbon atom when A represents an oxygen or sulphur atom or a group $(\text{CH}_2)_l\text{NR}^7$, or when A represents a bond B may also represent a C_{2-4} alkenylene chain;

R^1 represents a hydrogen atom or a C_{1-4} alkyl group;

- 15 m represents 1 or 2;

R^2 represents a hydrogen or a halogen atom, or a C_{1-4} alkyl, C_{1-4} alkoxy or C_{1-4} alkylthio group;


R^3 represents a hydrogen atom or a C_{1-4} alkoxy group;

R^4 represents a hydrogen atom or a C_{1-4} alkyl or C_{1-4} alkoxy group;

- 20 R^5 represents a hydrogen atom or R^1 and R^5 together form a group $-(\text{CH}_2)_n-$ where n represents 1 or 2;


R^6 represents a hydrogen atom or a C_{1-4} alkoxy group;

the group




is attached at the benzene ring 3 or 4 position relative to the carboxamide substituent, provided that when the group is attached at the benzene ring 3 position 5 then R⁴ must be attached at the benzene ring 6 position; and

Z represents either Het,



or



- 10 Het represents an optionally substituted bicyclic or tricyclic ring selected from quinolin-4-yl, isoquinolin-1-yl, isoquinolin-3-yl, quinolin-3-yl, quinolin-2-yl, quinoxalin-2-yl, naphthalen-1-yl, naphthalen-2-yl, indol-2-yl, 4-oxo-4H-1-benzopyran-2-yl, phenazin-1-yl and phenothiazin-1-yl or an aryl substituted monocyclic ring selected from 2-aryl-4-thiazolyl, 2-aryl-5-thiazolyl, 5-aryl-2-thienyl,
- 15 2-aryl-4-triazolyl and 1-aryl-4-pyrazolyl where aryl represents a phenyl or pyridyl ring optionally substituted by a halogen atom or a trifluoromethyl, C₁₋₄ alkyl or C₁₋₄ alkoxy group. The above mentioned bicyclic or tricyclic rings may be unsubstituted or substituted by one, two or three groups selected from C₁₋₄ alkyl and C₁₋₄ alkoxy. Quinolin-4-yl rings may also be substituted in the ring 2 position by phenyl or phenyl

substituted by C₁₋₄ alkoxy. Indol-2-yl rings may also be substituted in the ring 3 position by benzoyl;

R⁸ represents a hydrogen or halogen atom or a C₁₋₄ alkyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, amino or nitro group;

5 p represents 1; or when R⁸ represents C₁₋₄ alkoxy p may also represent 2 or 3;

R⁹ represents a hydrogen or halogen atom or a C₁₋₄ alkyl, C₁₋₄ alkoxy or C₁₋₄ alkylthio group;

R¹⁰ and R¹¹ may each represent a hydrogen atom or together form a bond or a linking atom selected from -O- or -S-; and


10 X represents an oxygen atom or NR¹² (where R¹² represents a hydrogen atom or a C₁₋₄ alkyl group).

2. A compound according to Claim 1 in which R² and R³ each represent a C₁₋₄ alkoxy group and R⁶ represents a hydrogen atom.

3. A compound according to Claim 1 or Claim 2 in which R⁴ represents a
15 hydrogen atom.

4. A compound according to any preceding claim in which m represents 1 and R¹ and R⁵ together form a group -(CH₂)₂-.

5. A compound of formula (Ia).



20


wherein Z is as defined in Claim 1 above;

A represents an oxygen or a sulphur atom or a bond;

6. A compound according to Claim 5 in which Z represents Het as defined in
5 Claim 1 above.

The diagram shows a chemical structure of a substituted benzophenone. It consists of two benzene rings connected by a central carbonyl group ($\text{C}=\text{O}$). The left benzene ring has substituents labeled R^8 , R^9 , and R^{10} . The right benzene ring has substituents labeled R^7 and R^{11} . An arrow points downwards from the position between R^{11} and the carbonyl group.

8. A compound according to Claim 5 in which Z represents



9. A compound according to Claim 7 or Claim 8 in which R⁸ represents a hydrogen or fluorine atom or a C₁₋₄ alkoxy or C₁₋₄ alkyl group and R⁹ represents a hydrogen atom.

20 10. A compound according to any preceding claim for use in therapy.


11. A compound according to any of Claims 1 to 9 for use in the treatment of a mammal which is suffering from cancer, to improve or increase the efficacy of an anti-tumour drug, or increase or restore sensitivity of a tumour to an anti-tumour drug, or reverse or reduce resistance of a tumour to an anti-tumour drug.
- 5 12. Use of a compound according to any of Claims 1 to 9 for the manufacture of a medicament for the treatment of a mammal suffering from cancer, to improve or increase the efficacy of an anti-tumour drug, or increase or restore sensitivity of a tumour to an anti-tumour drug, or reverse or reduce resistance of a tumour to an anti-tumour drug.
- 10 13. A method of treatment of a mammal which is suffering from cancer, which method comprises administering to said mammal an effective amount of a compound according to any of Claims 1 to 9 to improve or increase the efficacy of an anti-tumour drug, or increase or restore sensitivity of a tumour to an anti-tumour drug, or reverse or reduce resistance of a tumour to an anti-tumour drug.
- 15 14. A pharmaceutical composition which comprises a compound according to any of Claims 1 to 9 together with one or more physiologically acceptable carriers or excipients.
15. A pharmaceutical composition which comprises an active amount of a compound according to any of Claims 1 to 9 for use in the treatment of a mammal
20 which is suffering from cancer, to improve or increase the efficacy of an anti-tumour drug, or increase or restore sensitivity of a tumour to an anti-tumour drug, or reverse or reduce resistance of a tumour to an anti-tumour drug.
16. A pharmaceutical composition according to Claim 14 or 15 in a form suitable for oral, buccal, parenteral or rectal administration.
- 25 17. A pharmaceutical composition according to any of Claims 14 to 16 in unit dosage form.
18. A product containing a compound according to any of Claims 1 to 9 and an anti-tumour drug as a combined preparation for simultaneous, separate or sequential use in treating cancer.

19. A compound according to any of Claims 1 to 9 and an anti-tumour drug in the presence of each other in the human or non-human animal body for use in treating cancer.


20. Product or process according to any of Claims 11 to 19 (except Claim 14) wherein the anti-tumour drug is selected from Vinca alkaloids, anthracyclines, taxol and derivatives thereof, podophyllotoxins, mitoxantrone, actinomycin, colchicine, gramicidine D, amsacrine or any drug having cross-resistance with the above drugs characterised by the so-called MDR phenotype.

21. A process for the preparation of a compound according to Claim 1 which comprises :

(A) reacting a compound of formula (II)




with a compound of formula (III)




in the presence of a coupling reagent; or

(B) reacting a compound of formula (IV)

20



(wherein Q represents a halogen atom) with a compound of formula (V)



5 or a salt thereof in the presence of an acid acceptor; with salt formation as an optional step subsequent to process (A) or (B).

22. Compounds according to any of Claims 1 to 9 substantially as herein described.

23. Compositions according to any of Claims 14 to 17 substantially as herein described.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 93/01802

| | | |
|---|---|--|
| I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶ | | |
| Accord: International Patent Classification (IPC) or to both National Classification and IPC | | |
| Int.Cl. 5 C07D217/04; C07C235/84; | A61K31/47; C07C233/80; | C07D401/12; C07D215/48; C07D335/16 C07D215/52 ./. |
| II. FIELDS SEARCHED | | |
| Minimum Documentation Searched ⁷ | | |
| Classification System | Classification Symbols | |
| Int.Cl. 5 | C07D ; C07C | |
| Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ | | |
| | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ | | |
| Category ¹⁰ | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ |
| A | EP,A,0 206 802 (DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND) 30 December 1986 see claims 1,12-15 --- | 1,10-20 |
| A | EP,A,0 172 744 (DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND) 26 February 1986 see claims 1,20-23 --- | 1,12-20 |
| A | JOURNAL OF MEDICINAL CHEMISTRY vol. 31, no. 3, March 1988, WASHINGTON US pages 707 - 712 BRIAN D. PALMER ET AL 'Potential antitumor agents.54.Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides' --- <div style="text-align: right;">-/--</div> | 1,12-20 |
| <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div> | | |
| IV. CERTIFICATION | | |
| Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">28 SEPTEMBER 1993</div> | | Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">- 4. 10. 93</div> |
| International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div> | | Signature of Authorized Officer <div style="text-align: center; font-weight: bold;">HENRY J.C.</div> |

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) | | |
|--|---|-----------------------|
| Category ° | Citation of Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No. |
| P,X | EP,A,0 494 623 (LABORATOIRES GLAXO SA) 15 July 1992 cited in the application see claims ----- | 1,12-20 |

INTERNATIONAL SEARCH REPORT

International Application N

PCT/EP 93/01802

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC⁵: C07D311/86; C07D217/26; C07D241/46⁻

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System |

Classification Symbols

IPC⁵

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹

| Category ⁹ | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ |
|-----------------------|--|-------------------------------------|
| | | |

⁹ Special categories of cited documents: ¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

Date of Mailing of this International Search Report

International Searching Authority

Signature of Authorized Officer

EUROPEAN PATENT OFFICE

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 93/01802

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 13 is directed to a method of treatment of the human body, the search has been carried out and based on the alleged effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

EP 9301802
SA 76742

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 28/09/93

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---------------------------------|----------------------|
| EP-A-0206802 | 30-12-86 | JP-A- 62048669 US-A- 4904659 | 03-03-87 27-02-90 |
| EP-A-0172744 | 26-02-86 | JP-A- 61112061 | 30-05-86 |
| EP-A-0494623 | 15-07-92 | AU-A- 1154392 WO-A- 9212132 | 17-08-92 23-07-92 |

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.